Targeting	O
of	O
p300	B-protein
to	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
via	O
CREB-Rel	O
cross-talk	O
during	O
mitogen	B-protein
and	O
oncogenic	O
molecular	O
signaling	O
in	O
activated	B-cell_type
T-cells	I-cell_type
.	O

In	O
this	O
report	O
,	O
we	O
explore	O
the	O
mechanisms	O
of	O
targeting	O
of	O
p300	B-protein
to	O
the	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
promoter	I-DNA
in	O
response	O
to	O
mitogenic	O
and	O
oncogenic	O
molecular	O
signals	O
.	O

Recruitment	O
of	O
p300	B-protein
by	O
cAMP-responsive	B-protein
element-binding	I-protein
protein-Rel	I-protein
cross-talk	O
at	O
the	O
composite	B-protein
CD28	I-protein
response	I-protein
element	I-protein
(	O
CD28RE	B-protein
)	O
-	O
TRE	B-DNA
element	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
essential	O
for	O
promoter	O
inducibility	O
during	O
T-cell	O
activation	O
,	O
and	O
CD28RE-TRE	B-DNA
is	O
the	O
exclusive	O
target	O
of	O
the	O
human	B-cell_type
T-cell	I-cell_type
lymphotropic	O
virus	O
type	O
I	O
oncoprotein	B-protein
Tax	I-protein
.	O

The	O
intrinsic	O
histone	O
acetyltransferase	O
activity	O
of	O
p300	B-protein
is	O
dispensable	O
for	O
activation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
and	O
the	O
N-terminal	B-protein
743	I-protein
residues	I-protein
contain	O
the	O
minimal	O
structural	O
requirements	O
for	O
synergistic	O
transactivation	O
of	O
the	O
CD28RE-TRE	B-DNA
,	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
and	O
endogenous	O
IL-2	B-DNA
gene	I-DNA
expression	O
.	O

Mutational	O
analysis	O
of	O
p300	B-protein
reveals	O
differential	O
structural	O
requirements	O
for	O
the	O
N-terminal	O
p300	O
module	O
by	O
individual	O
cis-elements	B-DNA
within	O
the	O
IL-2	B-DNA
promoter	I-DNA
.	O

These	O
findings	O
provide	O
evidence	O
that	O
p300	B-protein
assembles	O
at	O
the	O
IL-2	B-DNA
promoter	I-DNA
to	O
form	O
an	O
enhanceosome-like	O
signal	O
transduction	O
target	O
that	O
is	O
centrally	O
integrated	O
at	O
the	O
CD28RE-TRE	B-DNA
element	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
through	O
specific	O
protein	O
module-targeted	O
associations	O
in	O
activated	B-cell_type
T-cells	I-cell_type
.	O

THE	NULL
JOURNAL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
Vol	NULL
.	NULL

276	NULL
,	NULL
No	NULL
.	NULL

29	NULL
,	NULL
Issue	NULL
of	NULL
July	NULL
20	NULL
,	NULL
pp	NULL
.	NULL

27647-27656	NULL
,	NULL
2001	NULL
Printed	NULL
in	NULL
U.S.A	NULL
.	NULL

Targeting	NULL
of	NULL
p300	NULL
to	NULL
the	NULL
Interleukin-2	NULL
Promoter	NULL
via	NULL
CREB-Rel	NULL
Cross-talk	NULL
during	NULL
Mitogen	NULL
and	NULL
Oncogenic	NULL
Molecular	NULL
Signaling	NULL
in	NULL
Activated	NULL
T-cells*	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
October	NULL
20	NULL
,	NULL
2000	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
April	NULL
18	NULL
,	NULL
2001	NULL
Published	NULL
,	NULL
JBC	NULL
Papers	NULL
in	NULL
Press	NULL
,	NULL
April	NULL
19	NULL
,	NULL
2001	NULL
,	NULL
DOI	NULL
10.1074/jbe.MO09614200	NULL
Wayne	NULL
G.	NULL
Butscher	NULL
$	NULL
,	NULL
Cynthia	NULL
M.	NULL
Haggerty	NULL
}	NULL
,	NULL
Sohail	NULL
Chaudhry	NULL
$	NULL
§	NULL
,	NULL
and	NULL
Kevin	NULL
Gardner	NULL
#	NULL
]	NULL
From	NULL
the	NULL
{	NULL
Advanced	NULL
Technology	NULL
Center	NULL
,	NULL
Laboratory	NULL
of	NULL
Pathology	NULL
,	NULL
NCI	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892	NULL
and	NULL
the	NULL
§Department	NULL
of	NULL
Microbiology	NULL
,	NULL
Howard	NULL
University	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
Washington	NULL
,	NULL
D.	NULL
C.	NULL
20059	NULL
In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
explore	NULL
the	NULL
mechanisms	NULL
of	NULL
targeting	NULL
of	NULL
p300	NULL
to	NULL
the	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
mitogenic	NULL
and	NULL
oncogenic	NULL
molecular	NULL
signals	NULL
.	NULL

Recruitment	NULL
of	NULL
p300	NULL
by	NULL
cAMP-responsive	NULL
element-binding	NULL
pro-tein-Rel	NULL
cross-talk	NULL
at	NULL
the	NULL
composite	NULL
CD28	NULL
response	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
-TRE	NULL
element	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
essential	NULL
for	NULL
promoter	NULL
inducibility	NULL
during	NULL
T-cell	NULL
activation	NULL
,	NULL
and	NULL
CD28RE-TRE	NULL
is	NULL
the	NULL
exclusive	NULL
target	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
oncoprotein	NULL
Tax	NULL
.	NULL

The	NULL
intrinsic	NULL
histone	NULL
acetyltransferase	NULL
activity	NULL
of	NULL
p300	NULL
is	NULL
dispensable	NULL
for	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
and	NULL
the	NULL
N-terminal	NULL
743	NULL
residues	NULL
contain	NULL
the	NULL
minimal	NULL
structural	NULL
requirements	NULL
for	NULL
synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
,	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
and	NULL
endogenous	NULL
IL-2	NULL
gene	NULL
expression	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
p300	NULL
reveals	NULL
differential	NULL
structural	NULL
requirements	NULL
for	NULL
the	NULL
N-terminal	NULL
p300	NULL
module	NULL
by	NULL
individual	NULL
cis-elements	NULL
within	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

These	NULL
findings	NULL
provide	NULL
evidence	NULL
that	NULL
p300	NULL
assembles	NULL
at	NULL
the	NULL
IL-2	NULL
promoter	NULL
to	NULL
form	NULL
an	NULL
enhan-ceosome-like	NULL
signal	NULL
transduction	NULL
target	NULL
that	NULL
is	NULL
centrally	NULL
integrated	NULL
at	NULL
the	NULL
CD28RE-TRE	NULL
element	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
through	NULL
specific	NULL
protein	NULL
module-targeted	NULL
associations	NULL
in	NULL
activated	NULL
T-cells	NULL
.	NULL

The	NULL
role	NULL
of	NULL
nuclear	NULL
transcription	NULL
factors	NULL
and	NULL
coactivators	NULL
as	NULL
primary	NULL
targets	NULL
of	NULL
molecular	NULL
signaling	NULL
in	NULL
eukaryotic	NULL
cells	NULL
has	NULL
emerged	NULL
as	NULL
a	NULL
fundamental	NULL
concept	NULL
in	NULL
signal	NULL
transduction	NULL
biology	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

Detailed	NULL
functional	NULL
characterization	NULL
of	NULL
the	NULL
molecular	NULL
correlates	NULL
that	NULL
underlie	NULL
the	NULL
control	NULL
of	NULL
these	NULL
events	NULL
has	NULL
been	NULL
essential	NULL
to	NULL
our	NULL
understanding	NULL
of	NULL
their	NULL
importance	NULL
in	NULL
cellular	NULL
homeostasis	NULL
and	NULL
has	NULL
provided	NULL
key	NULL
insights	NULL
into	NULL
the	NULL
manner	NULL
in	NULL
which	NULL
they	NULL
become	NULL
deranged	NULL
during	NULL
oncogenic	NULL
transformation	NULL
.	NULL

The	NULL
study	NULL
of	NULL
molecular	NULL
signaling	NULL
events	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
activated	NULL
T-cells	NULL
has	NULL
led	NULL
to	NULL
several	NULL
important	NULL
paradigms	NULL
with	NULL
relevant	NULL
application	NULL
to	NULL
the	NULL
understanding	NULL
of	NULL
signal	NULL
transduction	NULL
and	NULL
gene	NULL
regulation	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
(	NULL
4-7	NULL
)	NULL
.	NULL

The	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
``	NULL
gene	NULL
is	NULL
a	NULL
key	NULL
molecular	NULL
signaling	NULL
*	NULL
The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

«	NULL
]	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Advanced	NULL
Technology	NULL
Center	NULL
,	NULL
Rm	NULL
.	NULL

1840	NULL
,	NULL
8717	NULL
Grovemont	NULL
Circle	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
20892-4605	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
301-496-1055	NULL
;	NULL
Fax	NULL
:	NULL
301-485-7558	NULL
;	NULL
E-mail	NULL
:	NULL
gardnerk	NULL
@	NULL
mail.nih.gov	NULL
.	NULL

*The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
IL-2	NULL
,	NULL
interleukin-2	NULL
;	NULL
CD28RE	NULL
,	NULL
CD28	NULL
response	NULL
element	NULL
;	NULL
B-Zip	NULL
,	NULL
basic	NULL
leucine	NULL
zipper	NULL
;	NULL
CREB	NULL
,	NULL
cAMP-responsive	NULL
element-binding	NULL
protein	NULL
;	NULL
NF	NULL
,	NULL
nuclear	NULL
factor	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
wt	NULL
,	NULL
wild	NULL
type	NULL
;	NULL
TPA	NULL
,	NULL
12	NULL
,	NULL
-O-tetradecanoylphorbol-13-acetate	NULL
;	NULL
TRE	NULL
,	NULL
TPA	NULL
response	NULL
element	NULL
;	NULL
ATF-1	NULL
activating	NULL
transcription	NULL
This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
target	NULL
in	NULL
activated	NULL
T-cells	NULL
and	NULL
plays	NULL
a	NULL
pivotal	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

As	NULL
such	NULL
it	NULL
has	NULL
become	NULL
a	NULL
model	NULL
system	NULL
through	NULL
which	NULL
the	NULL
fundamental	NULL
mechanisms	NULL
of	NULL
stimulus-evoked	NULL
responses	NULL
can	NULL
be	NULL
studied	NULL
.	NULL

Although	NULL
we	NULL
are	NULL
far	NULL
from	NULL
a	NULL
precise	NULL
understanding	NULL
of	NULL
the	NULL
``	NULL
fine	NULL
tuned	NULL
``	NULL
regulation	NULL
of	NULL
IL-2	NULL
,	NULL
there	NULL
is	NULL
general	NULL
agreement	NULL
that	NULL
many	NULL
of	NULL
the	NULL
molecular	NULL
signaling	NULL
events	NULL
,	NULL
set	NULL
in	NULL
motion	NULL
during	NULL
T-cell	NULL
activation	NULL
,	NULL
converge	NULL
on	NULL
a	NULL
300-bse	NULL
pair	NULL
region	NULL
just	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
(	NULL
4	NULL
,	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

This	NULL
region	NULL
is	NULL
often	NULL
referred	NULL
to	NULL
as	NULL
the	NULL
interleukin-2	NULL
proximal	NULL
promoter	NULL
.	NULL

A	NULL
common	NULL
theme	NULL
that	NULL
has	NULL
emerged	NULL
from	NULL
the	NULL
study	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
other	NULL
Ras-controlled	NULL
genes	NULL
is	NULL
that	NULL
they	NULL
are	NULL
modulated	NULL
by	NULL
the	NULL
activity	NULL
of	NULL
one	NULL
or	NULL
more	NULL
composite	NULL
gene	NULL
regulatory	NULL
elements	NULL
.	NULL

These	NULL
composite	NULL
sites	NULL
are	NULL
targeted	NULL
cooperatively	NULL
by	NULL
the	NULL
interaction	NULL
of	NULL
two	NULL
or	NULL
more	NULL
separate	NULL
transcription	NULL
factors	NULL
,	NULL
in	NULL
a	NULL
linked	NULL
fashion	NULL
,	NULL
to	NULL
provide	NULL
both	NULL
increased	NULL
specificity	NULL
and	NULL
stability	NULL
.	NULL

Recently	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
CD28	NULL
response	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
,	NULL
one	NULL
of	NULL
the	NULL
major	NULL
Rel-	NULL
«	NULL
B-controlled	NULL
sites	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
functions	NULL
as	NULL
a	NULL
composite	NULL
site	NULL
in	NULL
conjunction	NULL
with	NULL
a	NULL
3'-sequence	NULL
that	NULL
interacts	NULL
with	NULL
members	NULL
of	NULL
the	NULL
basic	NULL
leucine	NULL
zipper	NULL
(	NULL
B-Zip	NULL
)	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

This	NULL
composite	NULL
site	NULL
,	NULL
termed	NULL
the	NULL
CD28RE-TRE	NULL
(	NULL
CD28RE-AP1	NULL
)	NULL
,	NULL
is	NULL
located	NULL
at	NULL
position	NULL
-174	NULL
to	NULL
-146	NULL
within	NULL
the	NULL
proximal	NULL
IL-2	NULL
promoter	NULL
and	NULL
provides	NULL
a	NULL
sequence-specific	NULL
regulatory	NULL
interface	NULL
where	NULL
Rel	NULL
and	NULL
CREB-targeted	NULL
molecular	NULL
signaling	NULL
events	NULL
converge	NULL
in	NULL
synergy	NULL
with	NULL
p300	NULL
(	NULL
10-12	NULL
)	NULL
.	NULL

Human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
is	NULL
the	NULL
etiologic	NULL
agent	NULL
of	NULL
adult	NULL
T-cell	NULL
leukemia/lymphoma	NULL
and	NULL
the	NULL
demyelinating	NULL
syn-drome	NULL
,	NULL
tropical	NULL
spastic	NULL
paraparesis	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

The	NULL
genome	NULL
of	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
encodes	NULL
a	NULL
40-kDa	NULL
transactivator	NULL
protein	NULL
,	NULL
Tax	NULL
,	NULL
which	NULL
drives	NULL
oncogenic	NULL
transformation	NULL
of	NULL
human	NULL
T-lymphocytes	NULL
and	NULL
can	NULL
act	NULL
,	NULL
in	NULL
conjunction	NULL
with	NULL
Ras	NULL
,	NULL
to	NULL
promote	NULL
the	NULL
transformation	NULL
of	NULL
rodent	NULL
fibroblasts	NULL
(	NULL
15	NULL
)	NULL
.	NULL

In	NULL
infected	NULL
cells	NULL
,	NULL
Tax	NULL
can	NULL
act	NULL
to	NULL
increase	NULL
the	NULL
activation	NULL
of	NULL
target	NULL
cellular	NULL
genes	NULL
containing	NULL
nuclear	NULL
factor	NULL
(	NULL
NF	NULL
)	NULL
-	NULL
«	NULL
B	NULL
and	NULL
CREB/ATF	NULL
sites	NULL
by	NULL
up-regulating	NULL
the	NULL
activity	NULL
of	NULL
both	NULL
CREB/	NULL
ATF	NULL
and	NULL
Re/NF-	NULL
«	NULL
B	NULL
transcription	NULL
factors	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

IL-2	NULL
and	NULL
the	NULL
IL-2	NULL
receptor-	NULL
«	NULL
are	NULL
well	NULL
known	NULL
targets	NULL
of	NULL
Tax	NULL
activation	NULL
in	NULL
T-cells	NULL
(	NULL
15	NULL
,	NULL
18-20	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
ability	NULL
of	NULL
Tax	NULL
to	NULL
up-regulate	NULL
Rel/xB	NULL
function	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
the	NULL
sole	NULL
underlying	NULL
mechanism	NULL
for	NULL
its	NULL
action	NULL
at	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
many	NULL
details	NULL
of	NULL
its	NULL
true	NULL
mode	NULL
of	NULL
regulation	NULL
at	NULL
the	NULL
CD28RE-TRE	NULL
remain	NULL
debated	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

As	NULL
a	NULL
result	NULL
,	NULL
a	NULL
precise	NULL
accounting	NULL
of	NULL
the	NULL
role	NULL
of	NULL
Tax	NULL
at	NULL
the	NULL
IL-2	NULL
promoter	NULL
continues	NULL
to	NULL
be	NULL
elusive	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
analyze	NULL
the	NULL
mechanism	NULL
through	NULL
which	NULL
cross-talk	NULL
between	NULL
the	NULL
Rel/	NULL
«	NULL
B	NULL
and	NULL
ATF/CREB	NULL
signaling	NULL
pathways	NULL
together	NULL
with	NULL
p300	NULL
control	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
factor	NULL
one	NULL
;	NULL
UAS	NULL
,	NULL
upstream	NULL
activating	NULL
sequence	NULL
;	NULL
CBP	NULL
,	NULL
CREB-binding	NULL
protein	NULL
.	NULL

27647	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
27648	NULL
promoter	NULL
at	NULL
its	NULL
central	NULL
composite	NULL
enhancers	NULL
when	NULL
challenged	NULL
by	NULL
both	NULL
mitogens	NULL
and	NULL
the	NULL
T-cell	NULL
oncogene	NULL
fax	NULL
.	NULL

We	NULL
present	NULL
a	NULL
model	NULL
predicting	NULL
that	NULL
a	NULL
key	NULL
target	NULL
for	NULL
the	NULL
signal	NULL
transduction	NULL
pathways	NULL
generated	NULL
during	NULL
T-cell	NULL
activation	NULL
is	NULL
the	NULL
assembly	NULL
of	NULL
a	NULL
CD28RE-TRE	NULL
directed	NULL
``	NULL
enhanceosome-like	NULL
``	NULL
complex	NULL
at	NULL
the	NULL
IL-2	NULL
proximal	NULL
promoter	NULL
.	NULL

This	NULL
assembly	NULL
is	NULL
centrally	NULL
linked	NULL
to	NULL
distinct	NULL
domains	NULL
of	NULL
p300	NULL
through	NULL
multiple	NULL
,	NULL
yet	NULL
specific	NULL
,	NULL
combinatorial	NULL
interactions	NULL
with	NULL
factors	NULL
coordinately	NULL
bound	NULL
to	NULL
its	NULL
composite	NULL
gene	NULL
regulatory	NULL
elements	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Plasmids	NULL
CD28RE-TRE-CAT	NULL
,	NULL
IL-2	NULL
CAT	NULL
,	NULL
NF-AT-CAT	NULL
,	NULL
HIVkB-CAT	NULL
,	NULL
AP1-CAT	NULL
,	NULL
and	NULL
A56-CAT	NULL
parental	NULL
control	NULL
reporter	NULL
plasmids	NULL
have	NULL
been	NULL
described	NULL
(	NULL
10	NULL
,	NULL
22	NULL
)	NULL
.	NULL

The	NULL
NFIL-2A-CAT	NULL
reporter	NULL
was	NULL
constructed	NULL
by	NULL
inserting	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
sequence	NULL
AGCTTCACGATGTTTTACATATTACACATAT-TTTCAAAGA	NULL
into	NULL
the	NULL
HindIII	NULL
site	NULL
upstream	NULL
of	NULL
the	NULL
minimal	NULL
fos	NULL
promoter	NULL
of	NULL
A56-CAT	NULL
.	NULL

The	NULL
CRE-CAT	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr.	NULL
Maria	NULL
Laura	NULL
Avantaggiati	NULL
.	NULL

The	NULL
UAS-CAT	NULL
reporter	NULL
plasmids	NULL
contains	NULL
five	NULL
tandem	NULL
copies	NULL
of	NULL
the	NULL
UAS	NULL
Gal4	NULL
recognition	NULL
site	NULL
linked	NULL
to	NULL
an	NULL
E1B	NULL
minimal	NULL
promoter	NULL
and	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr.	NULL
Irene	NULL
Collins	NULL
(	NULL
NCT	NULL
)	NULL
.	NULL

The	NULL
Tax	NULL
expression	NULL
vector	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
p300	NULL
expression	NULL
vectors	NULL
used	NULL
in	NULL
this	NULL
study	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
Gal4-p300	NULL
truncation	NULL
mutants	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
dominant	NULL
interfering	NULL
expression	NULL
vector	NULL
of	NULL
Ras	NULL
(	NULL
N17Ras	NULL
)	NULL
was	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Dr.	NULL
Silvio	NULL
Gutkind	NULL
(	NULL
NIDCR	NULL
)	NULL
.	NULL

The	NULL
CREB	NULL
dominant	NULL
negative	NULL
vector	NULL
is	NULL
highly	NULL
selective	NULL
for	NULL
CREB/ATF	NULL
transactivation	NULL
in	NULL
T-cells	NULL
and	NULL
represses	NULL
CREB-dependent	NULL
transactivation	NULL
without	NULL
affecting	NULL
AP-1-dependent	NULL
transcriptional	NULL
activation	NULL
(	NULL
10	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
«	NULL
B-specific	NULL
superdominant	NULL
vector	NULL
is	NULL
a	NULL
non-hydrolyzable	NULL
I-xB	NULL
expression	NULL
vector	NULL
that	NULL
selectively	NULL
inhibits	NULL
xB-dependent	NULL
transactivation	NULL
without	NULL
inhibiting	NULL
transactivation	NULL
from	NULL
other	NULL
cis-elements	NULL
including	NULL
the	NULL
NF-AT	NULL
site	NULL
and	NULL
has	NULL
been	NULL
described	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
of	NULL
lysates	NULL
from	NULL
cells	NULL
transfected	NULL
with	NULL
cytomegalovirus-p300	NULL
expression	NULL
vectors	NULL
shows	NULL
that	NULL
coexpression	NULL
with	NULL
either	NULL
Ras	NULL
,	NULL
CREB	NULL
,	NULL
or	NULL
xB	NULL
dominant	NULL
inhibitors	NULL
does	NULL
not	NULL
alter	NULL
the	NULL
level	NULL
of	NULL
protein	NULL
produced	NULL
from	NULL
the	NULL
exogenous	NULL
genes	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
mutant	NULL
Tax	NULL
expression	NULL
vectors	NULL
peTax	NULL
M47	NULL
,	NULL
peTax	NULL
M22	NULL
,	NULL
and	NULL
the	NULL
peTax	NULL
wt	NULL
control	NULL
were	NULL
a	NULL
gift	NULL
from	NULL
Warner	NULL
C.	NULL
Greene	NULL
(	NULL
J.	NULL
David	NULL
Gladstone	NULL
Institutes	NULL
)	NULL
and	NULL
have	NULL
been	NULL
described	NULL
extensively	NULL
(	NULL
16	NULL
)	NULL
.	NULL

A	NULL
simple	NULL
screen	NULL
for	NULL
functional	NULL
domains	NULL
within	NULL
the	NULL
N-terminal	NULL
748	NULL
amino	NULL
acids	NULL
of	NULL
p300	NULL
in	NULL
the	NULL
Gal4-p300	NULL
fusion	NULL
constructs	NULL
was	NULL
designed	NULL
by	NULL
mutating	NULL
4	NULL
of	NULL
10	NULL
N-terminal	NULL
sequences	NULL
that	NULL
were	NULL
predicted	NULL
to	NULL
assume	NULL
an	NULL
a-	NULL
helical	NULL
structure	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Chou	NULL
and	NULL
Fasman	NULL
.	NULL

The	NULL
targeted	NULL
regions	NULL
were	NULL
arbitrarily	NULL
referred	NULL
to	NULL
as	NULL
:	NULL
helix	NULL
I	NULL
,	NULL
residues	NULL
21-82	NULL
;	NULL
helix	NULL
II	NULL
,	NULL
residues	NULL
72-85	NULL
;	NULL
helix	NULL
VIII	NULL
,	NULL
residues	NULL
600-616	NULL
;	NULL
and	NULL
helix	NULL
IX	NULL
,	NULL
residues	NULL
633-663	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

The	NULL
a-helical	NULL
structure	NULL
was	NULL
disrupted	NULL
in	NULL
either	NULL
single	NULL
or	NULL
double	NULL
mutants	NULL
by	NULL
the	NULL
substitution	NULL
of	NULL
three	NULL
proline	NULL
residues	NULL
for	NULL
three	NULL
consecutive	NULL
residues	NULL
in	NULL
the	NULL
center	NULL
of	NULL
each	NULL
of	NULL
the	NULL
putative	NULL
a-helical	NULL
segments	NULL
described	NULL
above	NULL
.	NULL

The	NULL
mutations	NULL
were	NULL
introduced	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
using	NULL
the	NULL
QuikChange	NULL
site-directed	NULL
mutagenesis	NULL
kit	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
CA	NULL
)	NULL
.	NULL

Primer	NULL
Pairs	NULL
Used	NULL
for	NULL
Amino	NULL
Acid	NULL
Substitutions	NULL
Helix	NULL
I	NULL
(	NULL
Ser-24	NULL
,	NULL
Ala-25	NULL
,	NULL
Ser-26	NULL
)	NULL
-AGTTGACTGTATCGTCTCCGGC-CCTCTCGGCGCCTCCTCCTGATGGCACAGATTTTGGCTCTCTATT-	NULL
and	NULL
GTCGTGCTCCAAGTCAAATAGAGAG-CCAAAATCTGTGCCATCAGGAGGAGGCGCCGAGAGGGCCGGAG-	NULL
Helix	NULL
II	NULL
(	NULL
His-78	NULL
,	NULL
Lys-79	NULL
,	NULL
Gin-80	NULL
)	NULL
-CAAGTCTTGGCATGGTACAAG-ATGCAGCTTCTAAACCTCCTCCTCTGTCAGAATTGCTGCGATCTG-	NULL
and	NULL
TAGGGGAACTACCAGATCGCAGCAATTCT-GACAGAGGAGGAGGTTTAGAAGCTGCATCTTGTACCATGCCAAG-	NULL
Helix	NULL
VIII	NULL
(	NULL
Met-605	NULL
,	NULL
GLu-606	NULL
,	NULL
Asn-607	NULL
)	NULL
-	NULL
CCTACGCCGGATCCTG-CTGCTTTAAAAGACAGACGGCCTCCTCCTCTAGTTGCATATGCT	NULL
CGGAAAGTTGAAGGGGACATG	NULL
and	NULL
CATGTCCCCTTCAACTTTCC	NULL
GAGCATATGCAACTAGAGGAGGAGGCCGTCTGTCTTTTAAAGCA-GCAGGATCCGGCGTAGG	NULL
.	NULL

Helix	NULL
IX	NULL
(	NULL
Leu-644	NULL
,	NULL
Glu-645	NULL
,	NULL
Glu-646	NULL
)	NULL
-CCACCTTCTAGCTGAGAA-AATCTATAAGATCCAGAAAGAACCTCCTCCTAAACGAAGGACCA-	NULL
and	NULL
GGTAGCATGTTCTGCT-TCTGTAGTCTGGTCCTTCGTTTAGGAGGAGGTTCTTTCTGGATCT-	NULL
The	NULL
substitution	NULL
of	NULL
alanine	NULL
for	NULL
Tyr-638	NULL
within	NULL
the	NULL
p300	NULL
KIX	NULL
domain	NULL
(	NULL
Y638A	NULL
mutant	NULL
)	NULL
was	NULL
also	NULL
accomplished	NULL
by	NULL
site	NULL
directed	NULL
mutagenesis	NULL
,	NULL
as	NULL
described	NULL
above	NULL
,	NULL
using	NULL
the	NULL
primers	NULL
(	NULL
TCTAGTTCTTTCTGGATCTT	NULL
T-cell	NULL
Signaling	NULL
via	NULL
p300-Mediated	NULL
CREB-Rel	NULL
Cross-talk	NULL
GGCGATTTTCTCAGCTAGAAGGT	NULL
)	NULL
and	NULL
(	NULL
ACCTTCTAGCTGAGAAAA-TCGCCAAGATCCAGAAAGAACTAGA	NULL
)	NULL
.	NULL

The	NULL
IL-2	NULL
mutant	NULL
TRE	NULL
CAT	NULL
reporter	NULL
plasmid	NULL
contains	NULL
the	NULL
IL-2	NULL
flanking	NULL
region	NULL
from	NULL
-575	NULL
to	NULL
+47	NULL
with	NULL
a	NULL
3-base	NULL
substitution	NULL
at	NULL
the	NULL
TRE	NULL
portions	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
composite	NULL
site	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

84	NULL
)	NULL
.	NULL

This	NULL
reporter	NULL
mutant	NULL
was	NULL
constructed	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
IL-2-CAT	NULL
plasmid	NULL
using	NULL
the	NULL
primers	NULL
GTTTAAAGAAATTCCAAAGCAACATCAGAAGAGGAAAAATG	NULL
and	NULL
CATTTTTCCTCTTCTGATGTTGCTTTGGAATTTCTTTAAAC	NULL
and	NULL
was	NULL
provided	NULL
by	NULL
Dr.	NULL
V	NULL
.	NULL

Doseeva	NULL
.	NULL
``	NULL

Cell	NULL
Culture	NULL
and	NULL
Transfection	NULL
Assays	NULL
Jurkat	NULL
T-cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
medium	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
and	NULL
100	NULL
units/ml	NULL
penicillin/streptomycin	NULL
at	NULL
37°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

Cells	NULL
(	NULL
1-2	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
resuspended	NULL
in	NULL
250	NULL
ul	NULL
of	NULL
ice-cold	NULL
phosphate	NULL
buffer	NULL
with	NULL
2.5-8	NULL
ug	NULL
of	NULL
reporter	NULL
plasmid	NULL
and	NULL
1-8	NULL
ug	NULL
of	NULL
the	NULL
indicated	NULL
expression	NULL
vectors	NULL
followed	NULL
by	NULL
electroporation	NULL
(	NULL
200	NULL
V	NULL
,	NULL
1180	NULL
microfarads	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
5	NULL
ml	NULL
of	NULL
complete	NULL
RPMI	NULL
at	NULL
37°C	NULL
.	NULL

After	NULL
transfection	NULL
and	NULL
resuspension	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
either	NULL
left	NULL
unstimulated	NULL
or	NULL
were	NULL
stimulated	NULL
with	NULL
the	NULL
indicated	NULL
combinations	NULL
of	NULL
1	NULL
uM	NULL
ionomycin	NULL
(	NULL
Calbiochem	NULL
)	NULL
,	NULL
50	NULL
ng/ml	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
,	NULL
2	NULL
ug/ml	NULL
phytohemagglutinin	NULL
(	NULL
Murex	NULL
)	NULL
,	NULL
a	NULL
1:1,000	NULL
dilution	NULL
of	NULL
monoclonal	NULL
antibody	NULL
9.3	NULL
ascites	NULL
(	NULL
anti-CD28	NULL
)	NULL
(	NULL
Bris-tol-Myers	NULL
Squibb	NULL
Research	NULL
Institute	NULL
,	NULL
Seattle	NULL
)	NULL
,	NULL
and	NULL
a	NULL
1:1000	NULL
dilution	NULL
of	NULL
monoclonal	NULL
antibody	NULL
OKT3	NULL
ascites	NULL
(	NULL
ATCC	NULL
)	NULL
.	NULL

The	NULL
construction	NULL
of	NULL
Jurkat	NULL
cells	NULL
showing	NULL
stable	NULL
expression	NULL
of	NULL
the	NULL
Gal4-p300	NULL
(	NULL
amino	NULL
acids	NULL
1-748	NULL
)	NULL
was	NULL
established	NULL
by	NULL
selection	NULL
of	NULL
cells	NULL
transfected	NULL
with	NULL
a	NULL
peDNAS	NULL
vector	NULL
carrying	NULL
the	NULL
Gal4-p300	NULL
cDNA	NULL
and	NULL
a	NULL
neomycin	NULL
resistance	NULL
gene	NULL
.	NULL

Cells	NULL
were	NULL
selected	NULL
by	NULL
growth	NULL
in	NULL
medium	NULL
containing	NULL
1.6	NULL
mg/ml	NULL
G418	NULL
.	NULL

Resistant	NULL
pools	NULL
of	NULL
cells	NULL
were	NULL
screened	NULL
for	NULL
the	NULL
G4-p300	NULL
expression	NULL
by	NULL
transient	NULL
transfection	NULL
with	NULL
UAS-CAT	NULL
and	NULL
subsequent	NULL
CAT	NULL
assay	NULL
.	NULL

Positive	NULL
pools	NULL
of	NULL
cells	NULL
were	NULL
cloned	NULL
by	NULL
limiting	NULL
dilution	NULL
in	NULL
G418	NULL
and	NULL
screened	NULL
a	NULL
second	NULL
time	NULL
by	NULL
UAS-CAT	NULL
reporter	NULL
assay	NULL
.	NULL

All	NULL
transient	NULL
transfections	NULL
studies	NULL
were	NULL
performed	NULL
in	NULL
duplicate	NULL
or	NULL
triplicate	NULL
and	NULL
,	NULL
in	NULL
all	NULL
cases	NULL
,	NULL
are	NULL
representative	NULL
of	NULL
at	NULL
least	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

CAT	NULL
activity	NULL
in	NULL
cell	NULL
extracts	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Quantitation	NULL
of	NULL
the	NULL
CAT	NULL
activity	NULL
was	NULL
performed	NULL
using	NULL
a	NULL
Molecular	NULL
Dynamics	NULL
PhosphorImager	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

300	NULL
Protein-DNA	NULL
Binding	NULL
Assays	NULL
0.3-1.5	NULL
ug	NULL
of	NULL
affinity-purified	NULL
ATF-1/CREB	NULL
and	NULL
c-Rel	NULL
(	NULL
10	NULL
)	NULL
was	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
at	NULL
25	NULL
°C	NULL
in	NULL
binding	NULL
buffer	NULL
containing	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
60	NULL
mM	NULL
NaCl	NULL
,	NULL
0.05	NULL
%	NULL
Tween	NULL
20	NULL
,	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
5	NULL
mM	NULL
B-mercaptoceth-anol	NULL
with	NULL
500	NULL
ng	NULL
of	NULL
biotinylated	NULL
duplex	NULL
oligonucleotides	NULL
encoding	NULL
the	NULL
CD28RE-TRE	NULL
sequence	NULL
5'-TGGGGGTTTAAAGAAATTCCAAAGAGT-CATCAGAAGAGG-3	NULL
'	NULL
and	NULL
5-CCTCTTCTGATGACTCTTTGGAATTT-CTTTAAACCCCCA-3	NULL
'	NULL
at	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
50	NULL
pl	NULL
.	NULL

The	NULL
reaction	NULL
mix	NULL
was	NULL
then	NULL
placed	NULL
on	NULL
ice	NULL
and	NULL
incubated	NULL
with	NULL
2	NULL
ul	NULL
of	NULL
[	NULL
°°S	NULL
)	NULL
methionine-labeled	NULL
Gal4-p300	NULL
truncation	NULL
mutants	NULL
for	NULL
an	NULL
additional	NULL
15	NULL
min	NULL
.	NULL

20	NULL
ul	NULL
of	NULL
a	NULL
1:1	NULL
slurry	NULL
of	NULL
streptavidin-agarose	NULL
beads	NULL
(	NULL
Amersham	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
and	NULL
incubated	NULL
for	NULL
a	NULL
final	NULL
15	NULL
min	NULL
with	NULL
shaking	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
then	NULL
loaded	NULL
onto	NULL
200-ul	NULL
10	NULL
%	NULL
sucrose	NULL
cushions	NULL
containing	NULL
1	NULL
X	NULL
binding	NULL
buffer	NULL
and	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
at	NULL
500	NULL
x	NULL
g	NULL
for	NULL
5	NULL
min	NULL
The	NULL
sucrose	NULL
cushion	NULL
and	NULL
supernatant	NULL
were	NULL
removed	NULL
,	NULL
and	NULL
the	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
2.5	NULL
X	NULL
SDS-polyacrylamide	NULL
gel	NULL
buffer	NULL
and	NULL
separated	NULL
on	NULL
7.5	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
by	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
.	NULL

Bound	NULL
protein	NULL
was	NULL
visualized	NULL
by	NULL
autoradiography	NULL
,	NULL
and	NULL
the	NULL
percent	NULL
of	NULL
total	NULL
bound	NULL
labeled	NULL
protein	NULL
was	NULL
determined	NULL
on	NULL
a	NULL
Molecular	NULL
Dynamics	NULL
PhosphorImager	NULL
.	NULL

Antibodies	NULL
and	NULL
Western	NULL
Blots	NULL
and	NULL
Nuclear	NULL
Extracts	NULL
Western	NULL
blots	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
using	NULL
anti-Gal4-DNA	NULL
binding	NULL
domain	NULL
(	NULL
CLONTECH	NULL
and	NULL
Santa	NULL
Cruz	NULL
)	NULL
(	NULL
10	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
resting	NULL
or	NULL
stimulated	NULL
Ficoll-puri-fied	NULL
Jurkat	NULL
T-cells	NULL
following	NULL
electroporation	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
80	NULL
)	NULL
.	NULL

Determination	NULL
of	NULL
IL-2	NULL
IL-2	NULL
levels	NULL
were	NULL
determined	NULL
by	NULL
enzyme-linked	NULL
immunoabsorbent	NULL
analysis	NULL
using	NULL
the	NULL
Quantikine	NULL
immunoassay	NULL
kit	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

2C	NULL
.	NULL

M.	NULL
Haggerty	NULL
,	NULL
V.	NULL
Doseeva	NULL
,	NULL
W.	NULL
G.	NULL
Butscher	NULL
,	NULL
S.	NULL
Chaudhry	NULL
,	NULL
W.	NULL
Freebern	NULL
,	NULL
J.	NULL
I.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Gardner	NULL
,	NULL
manuscript	NULL
in	NULL
preparation	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
T-cell	NULL
Signaling	NULL
via	NULL
p300-Mediated	NULL
CREB-Rel	NULL
Cross-talk	NULL
27649	NULL
B	NULL
180	NULL
cxzzs	NULL
Unstim	NULL
c-	NULL
PMA/lonomycin	NULL
(	NULL
Stim	NULL
)	NULL
180	NULL
meses	NULL
Stim	NULL
+	NULL
anti-CD28	NULL
(	NULL
Co-stim	NULL
)	NULL
c-s-	NULL
Co-stim+	NULL
p300	NULL
Relative	NULL
CAT	NULL
Activity	NULL
p	NULL
A_	NULL
coment	NULL
cx	NULL
»	NULL
Unstim	NULL
+	NULL
Vector	NULL
--	NULL
Co-stim	NULL
+	NULL
Vector	NULL
meee	NULL
Co-stim	NULL
+	NULL
Dom	NULL
Neg	NULL
Dom	NULL
Neg	NULL
RAS	NULL
Relative	NULL
CAT	NULL
Activity	NULL
A56	NULL
CD28RE-TRE	NULL
0	NULL
&	NULL
--	NULL
>	NULL
Co-stim	NULL
+	NULL
Vector	NULL
cx	NULL
»	NULL
Unstim	NULL
+	NULL
Vector	NULL
I	NULL
meee	NULL
Co-stim	NULL
+	NULL
DP	NULL
IKB	NULL
Sup-Dom	NULL
to	NULL
IkB	NULL
Relative	NULL
CAT	NULL
Activity	NULL
A	NULL
-	NULL
alle	NULL
-All	NULL
+	NULL
p300	NULL
o	NULL
a	NULL
”	NULL
!	NULL

m	NULL
+	NULL
p300	NULL
U	NULL
&	NULL
Co-stim	NULL
+	NULL
Vector	NULL
«	NULL
x	NULL
»	NULL
Unstim	NULL
+	NULL
Vector	NULL
I	NULL
mem	NULL
Co-stim	NULL
+	NULL
Dom	NULL
Neg	NULL
20	NULL
Dom	NULL
Neg	NULL
``	NULL
|	NULL
CREB	NULL
Relative	NULL
CAT	NULL
Activity	NULL
0._E.D.I_Z	NULL
.	NULL

,	NULL
+	NULL
p300	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Tax	NULL
synergizes	NULL
with	NULL
p300	NULL
to	NULL
transactivate	NULL
the	NULL
CD28RE-TRE	NULL
.	NULL

Panel	NULL
A	NULL
and	NULL
B	NULL
,	NULL
Jurkat	NULL
T-cells	NULL
were	NULL
cotransfected	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
CD28RE-TRE-CAT	NULL
reporter	NULL
plasmid	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
right	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
{	NULL
ef	NULL
?	NULL
)	NULL

of	NULL
3	NULL
ug	NULL
of	NULL
the	NULL
p300	NULL
expression	NULL
vector	NULL
and	NULL
either	NULL
3	NULL
ug	NULL
of	NULL
Ras	NULL
dominant	NULL
negative	NULL
expression	NULL
vector	NULL
(	NULL
N17Ras	NULL
)	NULL
or	NULL
3	NULL
ug	NULL
of	NULL
control	NULL
cytomegalovirus	NULL
expression	NULL
vector	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
costimulated	NULL
with	NULL
50	NULL
ng	NULL
of	NULL
phorbol	NULL
12-myristate	NULL
18-acetate/ionomycin	NULL
and	NULL
1	NULL
uM	NULL
ionomycin	NULL
plus	NULL
anti-CD28	NULL
monoclonal	NULL
antibody	NULL
(	NULL
1:1,000	NULL
dilution	NULL
;	NULL
Co-sfim	NULL
)	NULL
.	NULL

Panel	NULL
C	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
CD28RE-TRE-CAT	NULL
and	NULL
8	NULL
ug	NULL
of	NULL
either	NULL
control	NULL
expression	NULL
vector	NULL
or	NULL
a	NULL
Rel/kB	NULL
dominant	NULL
negative	NULL
expression	NULL
vector	NULL
(	NULL
dominant	NULL
interfering	NULL
non-phosphorylated	NULL
IxB-a	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
3	NULL
ug	NULL
of	NULL
p300	NULL
expression	NULL
vector	NULL
.	NULL

Panel	NULL
!	NULL

D	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
CD28RE-TRE-CAT	NULL
and	NULL
3	NULL
ug	NULL
of	NULL
control	NULL
vector	NULL
or	NULL
3	NULL
ug	NULL
of	NULL
CREB	NULL
dominant	NULL
negative	NULL
expression	NULL
vector	NULL
.	NULL

RESULTS	NULL
Mitogen	NULL
Induction	NULL
of	NULL
CREB-Rel	NULL
Targeting	NULL
Pathways	NULL
Is	NULL
an	NULL
Essential	NULL
Component	NULL
of	NULL
Molecular	NULL
Signaling	NULL
at	NULL
the	NULL
IL-2	NULL
Proximal	NULL
Promoter	NULL
and	NULL
Acts	NULL
in	NULL
Synergy	NULL
with	NULL
p300-As	NULL
reported	NULL
previously	NULL
(	NULL
10	NULL
)	NULL
,	NULL
overexpression	NULL
of	NULL
p300	NULL
leads	NULL
to	NULL
synergistic	NULL
increases	NULL
in	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
CD28RE-TRE	NULL
gene	NULL
regulatory	NULL
element	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
in	NULL
response	NULL
to	NULL
the	NULL
well	NULL
characterized	NULL
T-cell	NULL
mitogens	NULL
phorbol	NULL
ester	NULL
and	NULL
ionomycin	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

The	NULL
dependence	NULL
of	NULL
this	NULL
synergy	NULL
on	NULL
intact	NULL
Ras-responsive	NULL
CREB	NULL
and	NULL
«	NULL
B	NULL
molecular	NULL
signaling	NULL
pathways	NULL
is	NULL
demonstrated	NULL
by	NULL
the	NULL
disruption	NULL
of	NULL
the	NULL
p300-controlled	NULL
CD28RE-TRE	NULL
transactivation	NULL
by	NULL
the	NULL
activity	NULL
of	NULL
three	NULL
previously	NULL
described	NULL
pathway-specific	NULL
in-hibitors	NULL
:	NULL
a	NULL
dominant	NULL
negative	NULL
CREB/ATF	NULL
(	NULL
CREB	NULL
leucine	NULL
zipper	NULL
with	NULL
acidic	NULL
extension	NULL
)	NULL
expression	NULL
vector	NULL
,	NULL
a	NULL
superdominant	NULL
I-	NULL
«	NULL
B	NULL
(	NULL
hydrolysis-resistant	NULL
I-	NULL
«	NULL
B-	NULL
«	NULL
mutant	NULL
,	NULL
Rel/xB	NULL
inhibitor	NULL
)	NULL
expression	NULL
vector	NULL
,	NULL
and	NULL
a	NULL
dominant	NULL
negative	NULL
vector	NULL
for	NULL
Ras	NULL
(	NULL
Asn-17	NULL
substitution	NULL
;	NULL
see	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
B-D	NULL
,	NULL
blockade	NULL
of	NULL
Ras	NULL
,	NULL
Re/	NULL
«	NULL
kB	NULL
,	NULL
or	NULL
CREB/ATF	NULL
effector	NULL
signaling	NULL
abrogates	NULL
mitogen-induced	NULL
transactivation	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
,	NULL
in	NULL
both	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
exogenous	NULL
p300	NULL
.	NULL

Tax	NULL
Targets	NULL
both	NULL
«	NULL
B	NULL
and	NULL
CREB-dependent	NULL
of	NULL
Elements	NULL
of	NULL
CD28RE-TRE	NULL
to	NULL
Transactivate	NULL
the	NULL
IL-2	NULL
Promoter	NULL
in	NULL
Synergy	NULL
with	NULL
p300-The	NULL
Tax	NULL
oncoprotein	NULL
has	NULL
pleiotropic	NULL
effects	NULL
on	NULL
a	NULL
variety	NULL
of	NULL
immediate	NULL
early	NULL
and	NULL
cytokine	NULL
genes	NULL
in	NULL
activated	NULL
T-cells	NULL
.	NULL

Several	NULL
earlier	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
a	NULL
major	NULL
target	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
Tax	NULL
oncoprotein	NULL
(	NULL
18	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Although	NULL
it	NULL
has	NULL
been	NULL
generally	NULL
reported	NULL
that	NULL
the	NULL
«	NULL
B	NULL
pathway	NULL
is	NULL
the	NULL
exclusive	NULL
target	NULL
of	NULL
Tax	NULL
action	NULL
at	NULL
the	NULL
IL-2	NULL
reporter	NULL
through	NULL
its	NULL
ability	NULL
to	NULL
increase	NULL
the	NULL
phosphorylation-dependent	NULL
degradation	NULL
of	NULL
the	NULL
I-	NULL
«	NULL
B	NULL
inhibitor	NULL
,	NULL
other	NULL
laboratories	NULL
have	NULL
suggested	NULL
roles	NULL
for	NULL
factors	NULL
distinct	NULL
from	NULL
NF-kB	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

Our	NULL
observation	NULL
that	NULL
the	NULL
TRE	NULL
half	NULL
of	NULL
the	NULL
IL-2	NULL
CD28RE-TRE	NULL
element	NULL
associates	NULL
with	NULL
ATF/CREB	NULL
B-Zip	NULL
factors	NULL
(	NULL
10	NULL
)	NULL
suggests	NULL
that	NULL
CREB	NULL
signaling	NULL
at	NULL
this	NULL
site	NULL
may	NULL
be	NULL
a	NULL
major	NULL
mechanism	NULL
through	NULL
which	NULL
Tax	NULL
acts	NULL
at	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

To	NULL
test	NULL
this	NULL
possibility	NULL
,	NULL
the	NULL
action	NULL
of	NULL
Tax	NULL
at	NULL
an	NULL
IL-2-CAT	NULL
reporter	NULL
construct	NULL
,	NULL
in	NULL
which	NULL
the	NULL
TRE	NULL
portion	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
composite	NULL
element	NULL
within	NULL
the	NULL
promoter	NULL
was	NULL
altered	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
TRE	NULL
)	NULL
,	NULL
was	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
promoter	NULL
sequence	NULL
(	NULL
wt	NULL
IL2	NULL
)	NULL
.	NULL

As	NULL
demonstrated	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
tax	NULL
in	NULL
either	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
27650	NULL
A	NULL
T-cell	NULL
Signaling	NULL
via	NULL
p300-Mediated	NULL
CREB-Rel	NULL
Cross-talk	NULL
CD28RE	NULL
_	NULL
__	NULL
mTRE	NULL
wt	NULL
|L2-m_u_t.T_I§E	NULL
‘	NULL
.TTTTCA	NULL
...	NULL
...	NULL
.	NULL

CD28RE	NULL
TRE	NULL
,	NULL
,	NULL
.	NULL

,	NULL
12	NULL
(	NULL
--	NULL
I	NULL
unstim	NULL
m	NULL
P/	NULL
2	NULL
10	NULL
-~	NULL
]	NULL
Co-Stim	NULL
.2	NULL
O	NULL
©	NULL
s|	NULL
_	NULL
wiL2-CAT	NULL
<	NULL
50	NULL
o	NULL
C	NULL
__	NULL
unstim	NULL
2	NULL
5	NULL
41	NULL
czzz	NULL
p300	NULL
+	NULL
P/	NULL
os	NULL
E	NULL
p300	NULL
+	NULL
Wt	NULL
Tax	NULL
g	NULL
Sm	NULL
-	NULL
40	NULL
a	NULL
a	NULL
€	NULL
~~	NULL
p300	NULL
+	NULL
m22	NULL
Tax	NULL
A2	NULL
0	NULL
35	NULL
4	NULL
i	NULL
IL2-mTRE-CAT	NULL
g	NULL
-	NULL
p300	NULL
+	NULL
m47	NULL
Tax	NULL
2	NULL
30	NULL
N	NULL
<	NULL
C	NULL
alk	NULL
|	NULL
_	NULL
§	NULL
=	NULL
0	NULL
pr	NULL
|	NULL
Tax	NULL
(	NULL
56	NULL
ng	NULL
)	NULL
-o-	NULL
-+	NULL
+	NULL
+	NULL
Loc	NULL
-	NULL
4+	NULL
+	NULL
+	NULL
>	NULL
20	NULL
wt	NULL
IL2-CAT	NULL
+o	NULL
+	NULL
4+	NULL
4+	NULL
++	NULL
oe	NULL
e	NULL
R	NULL
E2	NULL
L	NULL
®	NULL
u	NULL
}	NULL
.	NULL

mut-	NULL
IL2-CAT	NULL
_	NULL
=	NULL
--	NULL
-	NULL
--	NULL
-	NULL
_	NULL
++++++	NULL
fra	NULL
m	NULL
5	NULL
4	NULL
B	NULL
>	NULL
Relative	NULL
CAT	NULL
Activity	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Tax	NULL
targeting	NULL
of	NULL
the	NULL
IL-2	NULL
CD28RE-TRE	NULL
through	NULL
CREB/ATF	NULL
and	NULL
Rel/B	NULL
.	NULL

Panel	NULL
A	NULL
,	NULL
fop	NULL
,	NULL
shows	NULL
a	NULL
schematic	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
mutated	NULL
at	NULL
the	NULL
CREB/ATF	NULL
recognition	NULL
site	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
(	NULL
IL2-mutTRE	NULL
)	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
compared	NULL
with	NULL
wild	NULL
type	NULL
(	NULL
wt	NULL
IL2-CAT	NULL
)	NULL
.	NULL

Bottom	NULL
,	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
IL-2	NULL
reporter	NULL
plasmids	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
were	NULL
cotransfected	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
156	NULL
ng	NULL
of	NULL
Tax	NULL
expression	NULL
vector	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
stimulated	NULL
with	NULL
either	NULL
phorbol	NULL
ester	NULL
and	NULL
ionomycin	NULL
(	NULL
P/Z	NULL
)	NULL
or	NULL
phorbol	NULL
ester/ionomycin	NULL
plus	NULL
anti-CD28	NULL
antibodies	NULL
as	NULL
indicated	NULL
.	NULL

Panel	NULL
B	NULL
,	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
CD28RE-TRE-CAT	NULL
with	NULL
either	NULL
no	NULL
additions	NULL
,	NULL
156	NULL
ng	NULL
of	NULL
Tax	NULL
expression	NULL
vector	NULL
,	NULL
3	NULL
ug	NULL
of	NULL
p300	NULL
expression	NULL
vector	NULL
,	NULL
or	NULL
both	NULL
Tax	NULL
and	NULL
p300	NULL
expression	NULL
vectors	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
either	NULL
dominant	NULL
(	NULL
dominant	NULL
interfering	NULL
or	NULL
superdominant	NULL
)	NULL
expression	NULL
vectors	NULL
for	NULL
3	NULL
ug	NULL
of	NULL
Ras	NULL
,	NULL
8	NULL
ug	NULL
of	NULL
Rel/xB	NULL
,	NULL
or	NULL
3	NULL
ug	NULL
of	NULL
CREB	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and	NULL
phorbol	NULL
ester	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

Panel	NULL
C	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
the	NULL
CD28RE-TRE-CAT	NULL
reporter	NULL
with	NULL
or	NULL
without	NULL
3	NULL
ug	NULL
of	NULL
expression	NULL
vector	NULL
for	NULL
either	NULL
wild	NULL
type	NULL
Tax	NULL
or	NULL
Tax	NULL
mutants	NULL
defective	NULL
in	NULL
CREB-dependent	NULL
(	NULL
M47	NULL
)	NULL
or	NULL
Rel/kB-	NULL
dependent	NULL
(	NULL
M22	NULL
)	NULL
pathways	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
left	NULL
CD28RE-TRE-CAT	NULL
100	NULL
--	NULL
-	NULL
Rep	NULL
Alone	NULL
80	NULL
cz	NULL
?	NULL

TAX	NULL
(	NULL
156	NULL
ng	NULL
)	NULL
x~	NULL
p300	NULL
(	NULL
3ug	NULL
)	NULL
60	NULL
-	NULL
meam	NULL
Tax/p300	NULL
40	NULL
4	NULL
20	NULL
2	NULL
ed	NULL
_|	NULL
ﬁlﬁ	NULL
mi	NULL
PMA/IONO	NULL
+DN	NULL
+SupDomIkB	NULL
RAS	NULL
CD28RE-TRE-CAT	NULL
+DNCREB	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and	NULL
phorbol	NULL
ester	NULL
as	NULL
described	NULL
above	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
T-cell	NULL
Signaling	NULL
via	NULL
p300-Mediated	NULL
CREB-Rel	NULL
Cross-talk	NULL
27651	NULL
c-	NULL
gﬁstim	NULL
_	NULL
*	NULL
g/TStim	NULL
'	NULL
Unstim	NULL
Q	NULL
E	NULL
Unstim+Tax	NULL
4	NULL
?	NULL

Unstim+Tax	NULL
b	NULL
Elrllstim+Tax	NULL
3	NULL
*	NULL
meme	NULL
_	NULL
P/l+Tax	NULL
[	NULL
>	NULL
*	NULL
P/I+Tax	NULL
S	NULL
P/l+Tax	NULL
2	NULL
O	NULL
5	NULL
2	NULL
.	NULL

<	NULL
$	NULL
|_	NULL
15	NULL
<	NULL
<	NULL
<	NULL
O	NULL
O	NULL
(	NULL
3	NULL
02	NULL
.	NULL
)	NULL

10	NULL
(	NULL
]	NULL
_	NULL
>	NULL
J	NULL
10	NULL
(	NULL
I	NULL
;	NULL
,	NULL
G	NULL
T	NULL
G	NULL
@	NULL
0	NULL
©	NULL
e	NULL
3	NULL
r.	NULL
©	NULL
r	NULL
r	NULL
o	NULL
A	NULL
1A	NULL
H	NULL
o	NULL
,	NULL
I	NULL
(	NULL
o	NULL
CD28RE-TRE	NULL
NFAT	NULL
-CAT	NULL
NFIL-2A	NULL
D14	NULL
6	NULL
c	NULL
--	NULL
1	NULL
_	NULL
Unstim	NULL
zo	NULL
PA	NULL
>	NULL
___	NULL
R	NULL
>	NULL
``	NULL
|	NULL
z=	NULL
Unstim+Tax	NULL
Go	NULL
unstim	NULL
2	NULL
>	NULL
-	NULL
PH	NULL
S	NULL
mma	NULL
-	NULL
P/l+Tax	NULL
5	NULL
meg	NULL
Co-stim	NULL
g	NULL
3	NULL
1	NULL
€	NULL
;	NULL
a	NULL
<	NULL
i	NULL
Koos	NULL
<	NULL
<	NULL
C	NULL
O	NULL
0s	NULL
O	NULL
O	NULL
o	NULL
>	NULL
i	NULL
ﬂ	NULL
.2	NULL
e	NULL
©	NULL
s	NULL
o	NULL
/	NULL
1	NULL
o	NULL
mo	NULL
,	NULL
/	NULL
mo	NULL
,	NULL
,	NULL
41	NULL
C3	NULL
0	NULL
C	NULL
°	NULL
LL	NULL
é	NULL
Tax	NULL
-	NULL
S	NULL
+	NULL
3X	NULL
AP-1-CAT	NULL
Gal4-CREB	NULL
-	NULL
+	NULL
+	NULL
UAS-CAT	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Tax	NULL
selectively	NULL
targets	NULL
the	NULL
CD28RE-TRE	NULL
and	NULL
represses	NULL
AP-1-dependent	NULL
enhancers	NULL
.	NULL

Pane	NULL
!	NULL

A	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
reporter	NULL
plasmid	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
156	NULL
ng	NULL
of	NULL
wt	NULL
Tax	NULL
expression	NULL
vectors	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
stimulated	NULL
with	NULL
phorbol	NULL
ester	NULL
and	NULL
ionomycin	NULL
(	NULL
P/F	NULL
)	NULL
,	NULL
harvested	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

Panel	NULL
B	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
the	NULL
NF-AT	NULL
reporter	NULL
plasmid	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
156	NULL
ng	NULL
of	NULL
the	NULL
wt	NULL
Tax	NULL
expression	NULL
vectors	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
stimulated	NULL
and	NULL
assayed	NULL
for	NULL
reporter	NULL
activity	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Panel	NULL
C	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
the	NULL
NFIL-2A	NULL
reporter	NULL
plasmid	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
156	NULL
ng	NULL
of	NULL
the	NULL
wt	NULL
Tax	NULL
expression	NULL
vectors	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
stimulated	NULL
and	NULL
assayed	NULL
for	NULL
reporter	NULL
activity	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Panel	NULL
D	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
the	NULL
3X	NULL
AP-1	NULL
site	NULL
reporter	NULL
plasmid	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
156	NULL
ng	NULL
of	NULL
wt	NULL
Tax	NULL
expression	NULL
vectors	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
stimulated	NULL
and	NULL
assayed	NULL
for	NULL
reporter	NULL
activity	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Panel	NULL
E	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
2	NULL
ug	NULL
of	NULL
UAS-CAT	NULL
reporter	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
3	NULL
ug	NULL
of	NULL
Gal4-CREB	NULL
expression	NULL
vectors	NULL
alone	NULL
or	NULL
with	NULL
156	NULL
ng	NULL
of	NULL
cotransfected	NULL
Tax	NULL
expression	NULL
vector	NULL
.	NULL

Cells	NULL
were	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
with	NULL
P/I	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1:1,000	NULL
«	NULL
-CD28	NULL
antibodies	NULL
and	NULL
processed	NULL
for	NULL
reporter	NULL
activity	NULL
as	NULL
described	NULL
above	NULL
.	NULL

stimulated	NULL
or	NULL
costimulated	NULL
cells	NULL
is	NULL
completely	NULL
dependent	NULL
on	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
IL-2	NULL
CD28RE-TRE	NULL
3'-site	NULL
.	NULL

Reporter	NULL
studies	NULL
utilizing	NULL
a	NULL
single	NULL
copy	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
show	NULL
that	NULL
Tax	NULL
directly	NULL
up-regulates	NULL
the	NULL
CD28RE-TRE	NULL
,	NULL
and	NULL
this	NULL
response	NULL
is	NULL
increased	NULL
dramatically	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
exogenous	NULL
p300	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Tax-dependent	NULL
transactivation	NULL
is	NULL
repressed	NULL
effectively	NULL
by	NULL
dominant	NULL
negative	NULL
Ras	NULL
,	NULL
the	NULL
superdominant	NULL
I-	NULL
«	NULL
B	NULL
,	NULL
and	NULL
the	NULL
dominant	NULL
negative	NULL
CREB	NULL
expression	NULL
vectors	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
thus	NULL
demonstrating	NULL
that	NULL
Tax	NULL
targeting	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
and	NULL
its	NULL
synergy	NULL
with	NULL
p300	NULL
are	NULL
dependent	NULL
on	NULL
both	NULL
an	NULL
intact	NULL
«	NULL
B	NULL
and	NULL
CREB/ATF	NULL
signaling	NULL
pathway	NULL
.	NULL

This	NULL
point	NULL
is	NULL
demonstrated	NULL
further	NULL
by	NULL
using	NULL
mutants	NULL
of	NULL
Tax	NULL
which	NULL
are	NULL
deficient	NULL
in	NULL
transactivating	NULL
either	NULL
CREB/ATF	NULL
or	NULL
Rel/kB-dependent	NULL
genes	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

The	NULL
Tax	NULL
mutant	NULL
M47	NULL
can	NULL
activate	NULL
Rel/	NULL
«	NULL
B	NULL
pathways	NULL
but	NULL
not	NULL
the	NULL
CREB/ATF	NULL
pathways	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
M22	NULL
Tax	NULL
mutant	NULL
is	NULL
capable	NULL
of	NULL
activating	NULL
the	NULL
CREB/ATF	NULL
pathways	NULL
but	NULL
not	NULL
the	NULL
Rel/kB	NULL
pathways	NULL
(	NULL
16	NULL
)	NULL
.	NULL

As	NULL
demonstrated	NULL
in	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
coexpression	NULL
of	NULL
either	NULL
pathway-defective	NULL
Tax	NULL
mutant	NULL
produces	NULL
negligible	NULL
activation	NULL
of	NULL
CD28RE-TRE	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
p300	NULL
.	NULL

This	NULL
evidence	NULL
,	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
dramatic	NULL
effects	NULL
of	NULL
both	NULL
the	NULL
CREB	NULL
and	NULL
Rel/xB-specific	NULL
dominant	NULL
negative	NULL
vectors	NULL
on	NULL
Tax	NULL
induction	NULL
of	NULL
CD28RE-TRE	NULL
,	NULL
shows	NULL
that	NULL
the	NULL
primary	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
Tax	NULL
at	NULL
this	NULL
element	NULL
involves	NULL
a	NULL
dual	NULL
targeting	NULL
of	NULL
CREB-Rel	NULL
cross-talk	NULL
in	NULL
activated	NULL
T-cells	NULL
.	NULL

Tax	NULL
Selectively	NULL
Targets	NULL
the	NULL
IL-2	NULL
CD28RE-TRE	NULL
and	NULL
Not	NULL
the	NULL
NF-AT	NULL
,	NULL
NFIL-2A	NULL
,	NULL
or	NULL
an	NULL
AP-1	NULL
Consensus	NULL
Sites	NULL
in	NULL
Activated	NULL
T-cells-A	NULL
comparison	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
Tax	NULL
on	NULL
the	NULL
composite	NULL
elements	NULL
of	NULL
the	NULL
IL-2	NULL
promoters	NULL
demonstrates	NULL
that	NULL
the	NULL
CD28RE-TRE	NULL
composite	NULL
element	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
exclusively	NULL
targeted	NULL
by	NULL
the	NULL
Tax	NULL
oncogene	NULL
in	NULL
activated	NULL
T-cells	NULL
.	NULL

In	NULL
ionomycin-	NULL
and	NULL
phorbol	NULL
ester-stimulated	NULL
cells	NULL
,	NULL
Tax	NULL
coexpression	NULL
significantly	NULL
increases	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
transactivation	NULL
of	NULL
the	NULL
NF-AT	NULL
site	NULL
is	NULL
actually	NULL
repressed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tax	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

NFIL-2A	NULL
shows	NULL
negligible	NULL
influence	NULL
by	NULL
Tax	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
,	NULL
and	NULL
like	NULL
the	NULL
NF-AT	NULL
element	NULL
,	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
is	NULL
repressed	NULL
by	NULL
Tax	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
)	NULL
.	NULL

Prior	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
Tax	NULL
at	NULL
cellular	NULL
CRE	NULL
sites	NULL
is	NULL
via	NULL
the	NULL
enhanced	NULL
recruitment	NULL
of	NULL
p300/	NULL
CBP	NULL
to	NULL
the	NULL
KID	NULL
domain	NULL
of	NULL
CREB	NULL
bound	NULL
to	NULL
the	NULL
CRE	NULL
element	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

36	NULL
is	NULL
presented	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
to	NULL
demonstrate	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
27652	NULL
T-cell	NULL
Signaling	NULL
via	NULL
p300-Mediated	NULL
CREB-Rel	NULL
Cross-talk	NULL
p300	NULL
mutants	NULL
C/H1	NULL
C/H2___C/H3	NULL
TA	NULL
~-	NULL
TA	NULL
_	NULL
G	NULL
--	NULL
-3	NULL
CJ	NULL
C00	NULL
tT	NULL
--	NULL
-	NULL
(	NULL
C-3	NULL
B	NULL
T	NULL
<	NULL
C	NULL
~	NULL
&	NULL
t-p300	NULL
_	NULL
B	NULL
mutants	NULL
ars	NULL
3	NULL
M	NULL
,	NULL
.	NULL

x	NULL
10°	NULL
_	NULL
<	NULL
ma	NULL
200-	NULL
|_	NULL
A242-1737	NULL
1945-2414	NULL
10	NULL
5	NULL
8	NULL
o	NULL
6	NULL
m	NULL
4	NULL
3°	NULL
?	NULL

6	NULL
Z	NULL
Z	NULL
<	NULL
7	NULL
3	NULL
,	NULL
~	NULL
~	NULL
E	NULL
E	NULL
*_*	NULL
400	NULL
350	NULL
IL2-CAT	NULL
£2	NULL
?	NULL

300	NULL
i	NULL
2	NULL
250	NULL
|_	NULL
<	NULL
(	NULL
)	NULL
a	NULL
©	NULL
3	NULL
To	NULL
~	NULL
©	NULL
C	NULL
100	NULL
so	NULL
a	NULL
i	NULL
1	NULL
``	NULL
Jﬁ	NULL
(	NULL
-I	NULL
unstim	NULL
-	NULL
]	NULL
Stim	NULL
Stim	NULL
+	NULL
p300	NULL
1-743	NULL
aa	NULL
B	NULL
0.3	NULL
-1.5	NULL
ug	NULL
CD28RC	NULL
C	NULL
Affinity	NULL
Pure	NULL
M	NULL
,	NULL
x	NULL
10°	NULL
200-97	NULL
-68-	NULL
SDS	NULL
PAGE	NULL
C	NULL
--	NULL
J	NULL
Unstim	NULL
Cz	NULL
PII	NULL
XX	NULL
»	NULL
1-247	NULL
+	NULL
PII	NULL
im	NULL
1-743	NULL
+	NULL
P/l	NULL
sss	NULL
A2421737	NULL
+	NULL
P/	NULL
C	NULL
--	NULL
J	NULL
1945-2414	NULL
+	NULL
PII	NULL
CD28RE-TRE-CAT	NULL
1	NULL
o	NULL
a	NULL
o	NULL
o	NULL
o	NULL
60	NULL
4	NULL
40	NULL
Relative	NULL
CAT	NULL
Activity	NULL
20	NULL
4	NULL
``	NULL
A	NULL
30000	NULL
25000	NULL
<	NULL
p	NULL
20000	NULL
15000	NULL
4	NULL
10000	NULL
5000	NULL
Endogenous	NULL
IL2	NULL
Expression	NULL
(	NULL
picagrams/m	NULL
!	NULL
)	NULL

p300-1-743aa	NULL
expressing	NULL
jurkat	NULL
--	NULL
Unstim	NULL
§Onglml	NULL
PMA	NULL
<	NULL
==1	NULL
10ng/mIPMA	NULL
&	NULL
1uM	NULL
lonomycin	NULL
xxx	NULL
)	NULL
25ng/iml	NULL
PMA	NULL
&	NULL
1uM	NULL
lonomycin	NULL
mem	NULL
5O0ng/im	NULL
!	NULL

l	NULL
PMA	NULL
&	NULL
1uM	NULL
lonomycin	NULL
Jurkat	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

The	NULL
N-terminal	NULL
748	NULL
amino	NULL
acids	NULL
of	NULL
p300	NULL
are	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
recruitment	NULL
to	NULL
and	NULL
transactivation	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
and	NULL
IL-2	NULL
promoter	NULL
via	NULL
CREB/ATF	NULL
and	NULL
Rel/B	NULL
.	NULL

Panel	NULL
A	NULL
,	NULL
schematic	NULL
diagram	NULL
of	NULL
[	NULL
*°S	NULL
)	NULL
methionine-labeled	NULL
in	NULL
vitro	NULL
translated	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
T-cell	NULL
Signaling	NULL
via	NULL
p300-Mediated	NULL
CREB-Rel	NULL
Cross-talk	NULL
that	NULL
CREB	NULL
molecular	NULL
signaling	NULL
is	NULL
targeted	NULL
effectively	NULL
by	NULL
Tax	NULL
in	NULL
mitogen-activated	NULL
T-cells	NULL
.	NULL

In	NULL
this	NULL
experiment	NULL
,	NULL
low	NULL
levels	NULL
of	NULL
the	NULL
transfected	NULL
Gal4-CREB	NULL
fusion	NULL
are	NULL
synergistically	NULL
transacti-vated	NULL
when	NULL
coexpressed	NULL
with	NULL
Tax	NULL
.	NULL

Notably	NULL
,	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
is	NULL
maximal	NULL
with	NULL
phorbol	NULL
ester	NULL
and	NULL
ionomycin	NULL
alone	NULL
,	NULL
as	NULL
it	NULL
shows	NULL
little	NULL
increase	NULL
by	NULL
CD28	NULL
costimulation	NULL
.	NULL

The	NULL
N-terminal	NULL
743	NULL
amino	NULL
acids	NULL
of	NULL
p300	NULL
Are	NULL
Necessary	NULL
and	NULL
Sufficient	NULL
for	NULL
the	NULL
Mediation	NULL
of	NULL
CREB-Rel	NULL
Cross-talk	NULL
at	NULL
the	NULL
CD28RE-TRE	NULL
and	NULL
Potently	NULL
Transactivates	NULL
the	NULL
CD28RE-TRE	NULL
,	NULL
the	NULL
IL-2	NULL
Promoter	NULL
,	NULL
and	NULL
Endogenous	NULL
IL-2	NULL
Expression-The	NULL
transcriptional	NULL
activity	NULL
of	NULL
p300	NULL
at	NULL
individual	NULL
promoters	NULL
occurs	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
any	NULL
intrinsic	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
main	NULL
mechanism	NULL
of	NULL
p300	NULL
action	NULL
occurs	NULL
through	NULL
its	NULL
recruitment	NULL
to	NULL
individual	NULL
cis-elements	NULL
and	NULL
promoters	NULL
through	NULL
protein-protein	NULL
interactions	NULL
with	NULL
specific	NULL
transcription	NULL
factors	NULL
and	NULL
components	NULL
of	NULL
the	NULL
basal	NULL
transcriptional	NULL
apparatus	NULL
(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
CREB/ATF	NULL
binding	NULL
domain	NULL
has	NULL
been	NULL
localized	NULL
previously	NULL
to	NULL
the	NULL
KIX	NULL
domain	NULL
of	NULL
p300/CBP	NULL
,	NULL
which	NULL
encompasses	NULL
amino	NULL
acids	NULL
566-647	NULL
in	NULL
p300	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Two	NULL
separate	NULL
Rel/	NULL
«	NULL
B	NULL
binding	NULL
domains	NULL
have	NULL
been	NULL
identified	NULL
recently	NULL
:	NULL
one	NULL
in	NULL
the	NULL
N-terminal	NULL
594	NULL
amino	NULL
acids	NULL
of	NULL
p300	NULL
,	NULL
and	NULL
a	NULL
portion	NULL
spanning	NULL
residues	NULL
1572-2414	NULL
of	NULL
the	NULL
C	NULL
terminus	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

To	NULL
test	NULL
which	NULL
portions	NULL
of	NULL
p300	NULL
are	NULL
necessary	NULL
for	NULL
effective	NULL
recruitment	NULL
to	NULL
the	NULL
CD28RE-TRE	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
in	NULL
vitro	NULL
domain	NULL
requirements	NULL
of	NULL
p300	NULL
to	NULL
be	NULL
effectively	NULL
recruited	NULL
to	NULL
the	NULL
CD28RE-TRE	NULL
.	NULL

In	NULL
this	NULL
assay	NULL
,	NULL
biotinylated	NULL
duplex	NULL
oligonucleotides	NULL
encoding	NULL
a	NULL
single	NULL
copy	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
were	NULL
incubated	NULL
with	NULL
in	NULL
vitro	NULL
translated	NULL
Gal4	NULL
fusion	NULL
constructs	NULL
containing	NULL
different	NULL
portions	NULL
of	NULL
p300	NULL
(	NULL
see	NULL
upper	NULL
panel	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

Incubations	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
affinity-purified	NULL
CREB-Rel	NULL
complexes	NULL
obtained	NULL
from	NULL
phorbol	NULL
ester-	NULL
and	NULL
ionomycin-activated	NULL
Jurkat	NULL
T-cells	NULL
(	NULL
10	NULL
)	NULL
.	NULL

DNA-bound	NULL
versus	NULL
free	NULL
complexes	NULL
were	NULL
then	NULL
separated	NULL
by	NULL
centrifugation	NULL
with	NULL
avidin-coated	NULL
beads	NULL
.	NULL

In	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
the	NULL
portion	NULL
of	NULL
p300	NULL
containing	NULL
the	NULL
N-terminal	NULL
743	NULL
amino	NULL
acids	NULL
(	NULL
and	NULL
thus	NULL
both	NULL
Rel	NULL
and	NULL
CREB/ATF-1	NULL
binding	NULL
domains	NULL
)	NULL
was	NULL
effectively	NULL
recruited	NULL
to	NULL
the	NULL
CD28RE-TRE	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
purified	NULL
CREB-Rel	NULL
but	NULL
did	NULL
not	NULL
associate	NULL
with	NULL
CD28RE-TRE	NULL
in	NULL
their	NULL
absence	NULL
.	NULL

A	NULL
screen	NULL
of	NULL
the	NULL
CREB-Rel-dependent	NULL
recruitment	NULL
of	NULL
different	NULL
p300	NULL
truncation	NULL
mutants	NULL
(	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
to	NULL
the	NULL
CD28RE-TRE	NULL
shows	NULL
that	NULL
the	NULL
p300	NULL
mutant	NULL
encompassing	NULL
residues	NULL
1-743	NULL
is	NULL
the	NULL
most	NULL
efficiently	NULL
recruited	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
bottom	NULL
panel	NULL
)	NULL
.	NULL

Thus	NULL
the	NULL
portion	NULL
of	NULL
p300	NULL
which	NULL
contains	NULL
both	NULL
the	NULL
CREB/ATEF-1	NULL
binding	NULL
KIX	NULL
domain	NULL
and	NULL
the	NULL
N-terminal	NULL
Rel	NULL
binding	NULL
domain	NULL
is	NULL
the	NULL
most	NULL
efficiently	NULL
targeted	NULL
to	NULL
the	NULL
CD28RE-TRE	NULL
by	NULL
purified	NULL
CREB-Rel	NULL
complexes	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
this	NULL
portion	NULL
of	NULL
p300	NULL
(	NULL
resi-dues	NULL
1-743	NULL
)	NULL
is	NULL
the	NULL
most	NULL
effective	NULL
at	NULL
inducing	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
CD28RE-TRE-CAT	NULL
reporter	NULL
when	NULL
stimulated	NULL
by	NULL
phorbol	NULL
ester	NULL
and	NULL
ionomycin	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4D	NULL
)	NULL
.	NULL

The	NULL
small	NULL
amount	NULL
of	NULL
recruitment	NULL
and	NULL
transactivation	NULL
potential	NULL
demonstrated	NULL
by	NULL
the	NULL
C-terminal	NULL
1945-2414	NULL
residues	NULL
of	NULL
p300	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
is	NULL
consistent	NULL
with	NULL
a	NULL
single	NULL
Rel-interacting	NULL
domain	NULL
27653	NULL
identified	NULL
previously	NULL
in	NULL
that	NULL
region	NULL
(	NULL
38	NULL
)	NULL
.	NULL

The	NULL
N-terminal	NULL
748	NULL
amino	NULL
acids	NULL
of	NULL
p300	NULL
is	NULL
also	NULL
sufficient	NULL
to	NULL
superinduce	NULL
transactivation	NULL
of	NULL
the	NULL
entire	NULL
proximal	NULL
IL-2	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

4K	NULL
)	NULL
.	NULL

More-over	NULL
,	NULL
cells	NULL
that	NULL
stably	NULL
express	NULL
the	NULL
N-terminal	NULL
p300	NULL
residues	NULL
exhibit	NULL
increased	NULL
expression	NULL
of	NULL
endogenous	NULL
IL-2	NULL
(	NULL
Fig	NULL
.	NULL

4F	NULL
)	NULL
.	NULL

Cis-element	NULL
Recruitment	NULL
and	NULL
the	NULL
Transactivation	NULL
Potential	NULL
of	NULL
p300	NULL
Show	NULL
Differential	NULL
Dependence	NULL
on	NULL
Distinct	NULL
Structural	NULL
Domains	NULL
within	NULL
p300-To	NULL
determine	NULL
the	NULL
domain	NULL
dependence	NULL
of	NULL
p300	NULL
for	NULL
its	NULL
ability	NULL
to	NULL
interact	NULL
with	NULL
the	NULL
transcriptional	NULL
activa-tors	NULL
and	NULL
other	NULL
cofactors	NULL
that	NULL
regulate	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
a	NULL
series	NULL
of	NULL
domain	NULL
specific	NULL
mutants	NULL
was	NULL
generated	NULL
within	NULL
the	NULL
N-terminal	NULL
743	NULL
residues	NULL
of	NULL
p300	NULL
(	NULL
see	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
.	NULL

One	NULL
class	NULL
of	NULL
mutations	NULL
was	NULL
a	NULL
l-amino	NULL
acid	NULL
substitution	NULL
of	NULL
alanine	NULL
for	NULL
tyrosine	NULL
at	NULL
position	NULL
638	NULL
within	NULL
the	NULL
KIX	NULL
domain	NULL
of	NULL
p300	NULL
(	NULL
Y638A	NULL
p300	NULL
)	NULL
.	NULL

This	NULL
mutation	NULL
has	NULL
been	NULL
characterized	NULL
previously	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
the	NULL
interaction	NULL
of	NULL
CREB/ATF	NULL
with	NULL
the	NULL
KIX	NULL
domain	NULL
(	NULL
35	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
the	NULL
N-terminal	NULL
743	NULL
amino	NULL
acid	NULL
residues	NULL
of	NULL
p300	NULL
are	NULL
competent	NULL
to	NULL
activate	NULL
the	NULL
NF-AT	NULL
and	NULL
NFIL-2A	NULL
sites	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
consensus	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
sites	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
KIX	NULL
mutation	NULL
impairs	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
p300	NULL
N	NULL
terminus	NULL
to	NULL
induce	NULL
the	NULL
CD28RE-TRE	NULL
,	NULL
«	NULL
B	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
the	NULL
NF-AT	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
A	NULL
and	NULL
C	NULL
top	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
NFIL-2A	NULL
element	NULL
by	NULL
the	NULL
KIX	NULL
mutant	NULL
is	NULL
equivalent	NULL
to	NULL
wild	NULL
type	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
other	NULL
candidate	NULL
domains	NULL
of	NULL
p300	NULL
which	NULL
contribute	NULL
to	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
and	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
a	NULL
set	NULL
of	NULL
p300	NULL
N-terminal	NULL
mutants	NULL
was	NULL
derived	NULL
by	NULL
substituting	NULL
3	NULL
consecutive	NULL
proline	NULL
residues	NULL
in	NULL
the	NULL
center	NULL
of	NULL
9	NULL
predicted	NULL
a-helical	NULL
regions	NULL
within	NULL
the	NULL
p300	NULL
748-amino	NULL
acid	NULL
N	NULL
terminus	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

With	NULL
the	NULL
exception	NULL
of	NULL
the	NULL
double	NULL
mutant	NULL
II/IX	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
each	NULL
of	NULL
the	NULL
p300	NULL
mutants	NULL
showed	NULL
expression	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
fusion	NULL
protein	NULL
in	NULL
activated	NULL
Jurkat	NULL
T-cells	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
inset	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
these	NULL
mu-tants	NULL
,	NULL
including	NULL
the	NULL
p300	NULL
Y638A	NULL
substitution	NULL
,	NULL
was	NULL
assayed	NULL
for	NULL
their	NULL
function	NULL
as	NULL
Gal4	NULL
fusions	NULL
when	NULL
cotransfected	NULL
with	NULL
either	NULL
the	NULL
recruitment-dependent	NULL
CD28RE-TRE	NULL
or	NULL
the	NULL
recruitment-independent	NULL
(	NULL
recruitment	NULL
bypass	NULL
)	NULL
UAS-CAT	NULL
reporters	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
top	NULL
and	NULL
bottom	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5C	NULL
,	NULL
although	NULL
the	NULL
KIX	NULL
Y638A	NULL
mutant	NULL
is	NULL
deficient	NULL
in	NULL
transactivating	NULL
the	NULL
CD28RE-TRE	NULL
,	NULL
it	NULL
has	NULL
near	NULL
wild	NULL
type	NULL
activity	NULL
in	NULL
the	NULL
recruitment	NULL
bypass	NULL
assay	NULL
.	NULL

This	NULL
functional	NULL
dissociation	NULL
between	NULL
the	NULL
intrinsic	NULL
transactivation	NULL
potential	NULL
and	NULL
recruitment	NULL
is	NULL
also	NULL
observed	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
with	NULL
the	NULL
helix	NULL
IX	NULL
mutants	NULL
.	NULL

Interestingly	NULL
,	NULL
both	NULL
of	NULL
these	NULL
mutants	NULL
contain	NULL
substitutions	NULL
in	NULL
the	NULL
a-helical	NULL
regions	NULL
of	NULL
the	NULL
KIX	NULL
domain	NULL
as	NULL
determined	NULL
by	NULL
its	NULL
solution	NULL
structure	NULL
.	NULL

Of	NULL
note	NULL
is	NULL
that	NULL
mutation	NULL
of	NULL
the	NULL
helix	NULL
II	NULL
domain	NULL
of	NULL
p300	NULL
results	NULL
in	NULL
a	NULL
gain-of-function	NULL
mutant	NULL
that	NULL
has	NULL
above	NULL
wild	NULL
type	NULL
inducibility	NULL
in	NULL
both	NULL
the	NULL
CD28RE-TRE	NULL
recruitment	NULL
assay	NULL
and	NULL
the	NULL
recruitment	NULL
bypass	NULL
experiments	NULL
,	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
stimulation	NULL
.	NULL

This	NULL
observation	NULL
could	NULL
partially	NULL
reflect	NULL
a	NULL
slight	NULL
increased	NULL
stability	NULL
of	NULL
this	NULL
protein	NULL
over	NULL
the	NULL
wild	NULL
type	NULL
as	NULL
suggested	NULL
by	NULL
the	NULL
Western	NULL
blot	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
inset	NULL
)	NULL
;	NULL
however	NULL
,	NULL
truncation	NULL
mutants	NULL
of	NULL
p300	NULL
(	NULL
see	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
.	NULL

TA	NULL
,	NULL
transactivation	NULL
domains	NULL
.	NULL

C/H	NULL
,	NULL
cysteine/histidine-rich	NULL
regions	NULL
.	NULL

Panel	NULL
B	NULL
,	NULL
biotinylated	NULL
CD28RE-TRE	NULL
oligonucleotides	NULL
(	NULL
see	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
*°S-labeled	NULL
p300	NULL
(	NULL
amino	NULL
acids	NULL
1-748	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
increasing	NULL
amounts	NULL
(	NULL
0.08-1.5	NULL
pg	NULL
)	NULL
of	NULL
DNA	NULL
affinity-	NULL
purified	NULL
ATF-1/CREB	NULL
and	NULL
Rel	NULL
derived	NULL
from	NULL
mitogen-activated	NULL
Jurkat	NULL
T-cell	NULL
nuclear	NULL
extracts	NULL
(	NULL
10	NULL
)	NULL
(	NULL
see	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
.	NULL

After	NULL
incubation	NULL
,	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
precipitated	NULL
with	NULL
avidin-coated	NULL
beads	NULL
.	NULL

The	NULL
pellets	NULL
were	NULL
washed	NULL
,	NULL
eluted	NULL
into	NULL
SDS-polyacrylamide	NULL
gel	NULL
buffer	NULL
,	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
7.5	NULL
%	NULL
Laemmli	NULL
gel	NULL
.	NULL

Panel	NULL
C	NULL
,	NULL
top	NULL
,	NULL
the	NULL
indicated	NULL
*°8-labeled	NULL
p300	NULL
truncation	NULL
mutants	NULL
were	NULL
incubated	NULL
with	NULL
0.75	NULL
pug	NULL
of	NULL
affinity-purified	NULL
ATF-1/CREB-Rel	NULL
and	NULL
biotinylated	NULL
CD28RE-TRE	NULL
nucleotides	NULL
(	NULL
see	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
.	NULL

DNA-associated	NULL
p300	NULL
complexes	NULL
were	NULL
visualized	NULL
as	NULL
described	NULL
in	NULL
panel	NULL
B.	NULL
Boffom	NULL
,	NULL
quantitation	NULL
of	NULL
the	NULL
percent	NULL
bound	NULL
*°S-labeled	NULL
truncation	NULL
mutant/total	NULL
added	NULL
(	NULL
see	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
.	NULL

Pane	NULL
!	NULL

D	NULL
,	NULL
Jurkat	NULL
T-cells	NULL
were	NULL
cotransfected	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
3	NULL
ug	NULL
of	NULL
the	NULL
expression	NULL
vectors	NULL
encoding	NULL
the	NULL
p300	NULL
truncation	NULL
mutants	NULL
described	NULL
in	NULL
pare	NULL
!	NULL

A	NULL
and	NULL
4	NULL
ug	NULL
of	NULL
the	NULL
CD28RE-TRE-CAT	NULL
reporter	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
following	NULL
either	NULL
no	NULL
treatment	NULL
or	NULL
stimulation	NULL
with	NULL
phorbol	NULL
12-myristate	NULL
18-acetate	NULL
and	NULL
ionomycin	NULL
(	NULL
P/Z	NULL
)	NULL
.	NULL

Panel	NULL
E	NULL
,	NULL
Jurkat	NULL
T-cells	NULL
were	NULL
transfected	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
the	NULL
IL-2-CAT	NULL
reporter	NULL
plasmid	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
3	NULL
ug	NULL
of	NULL
p300	NULL
(	NULL
amino	NULL
acids	NULL
1-748	NULL
)	NULL
expression	NULL
vectors	NULL
and	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
stimulated	NULL
with	NULL
phorbol	NULL
ester	NULL
and	NULL
ionomycin	NULL
prior	NULL
to	NULL
assaying	NULL
for	NULL
reporter	NULL
activity	NULL
.	NULL

Panel	NULL
F	NULL
,	NULL
parent	NULL
Jurkat	NULL
T-cells	NULL
and	NULL
Jurkat	NULL
cells	NULL
selected	NULL
for	NULL
stable	NULL
expression	NULL
of	NULL
the	NULL
N-terminal	NULL
amino	NULL
acids	NULL
(	NULL
1-748	NULL
)	NULL
p300	NULL
sequences	NULL
(	NULL
see	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
were	NULL
evaluated	NULL
for	NULL
endogenous	NULL
IL-2	NULL
expression	NULL
and	NULL
secretion	NULL
in	NULL
response	NULL
to	NULL
treatment	NULL
with	NULL
either	NULL
no	NULL
additions	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
phorbol	NULL
ester	NULL
(	NULL
PMA	NULL
)	NULL
with	NULL
or	NULL
without	NULL
1	NULL
uM	NULL
ionomycin	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
27654	NULL
T-cell	NULL
Signaling	NULL
via	NULL
p300-Mediated	NULL
CREB-Rel	NULL
Cross-talk	NULL
60	NULL
A	NULL
--	NULL
-	NULL
no	NULL
addition	NULL
3X-NFAT	NULL
C	NULL
140	NULL
``	NULL
o	NULL
mio	NULL
CD28RE-TRE-CAT	NULL
|	NULL
Y638A	NULL
p300	NULL
1-743	NULL
120	NULL
iz	NULL
=	NULL
&	NULL
1	NULL
Reporter	NULL
alone	NULL
3	NULL
40	NULL
100	NULL
|	NULL
2	NULL
$	NULL
5500	NULL
[	NULL
1-243	NULL
aa	NULL
)	NULL
O	NULL
3	NULL
mutan	NULL
<	NULL
HIV-	NULL
«	NULL
B	NULL
4	NULL
Helix	NULL
I	NULL
mutant	NULL
IE	NULL
30	NULL
3X-AP1	NULL
80	NULL
5	NULL
Helix	NULL
II	NULL
mutant	NULL
(	NULL
6	NULL
Helix	NULL
VIII	NULL
mutant	NULL
o	NULL
so	NULL
7	NULL
Helix	NULL
IX	NULL
mutant	NULL
2	NULL
20	NULL
8	NULL
-	NULL
Helix	NULL
IY638A	NULL
mutant	NULL
~	NULL
£	NULL
>	NULL
>	NULL
9	NULL
Helix	NULL
IVIX	NULL
mutant	NULL
é	NULL
§	NULL
NF-IL2A	NULL
I	NULL
10	NULL
i=	NULL
``	NULL
4s	NULL
i	NULL
=	NULL
Y	NULL
zo	NULL
|	NULL
s	NULL
p	NULL
[	NULL
[	NULL
§	NULL
<	NULL
C	NULL
,	NULL
TIV	NULL
fap	NULL
<	NULL
4-s-4	NULL
%	NULL
13-13-37	NULL
i	NULL
«	NULL
en	NULL
xiii—m	NULL
STIM	NULL
(	NULL
P/	NULL
)	NULL
5	NULL
1	NULL
234	NULL
5	NULL
67	NULL
8	NULL
9	NULL
1234	NULL
567	NULL
8	NULL
9	NULL
35	NULL
B	NULL
Domain	NULL
Disrupted	NULL
Mutants	NULL
of	NULL
the	NULL
p300	NULL
N-terminus	NULL
@	NULL
1232	NULL
“	NULL
U	NULL
?	NULL

“	NULL
-	NULL
184171	NULL
rsezss	NULL
sisast	NULL
seo	NULL
ser	NULL
assars	NULL
cooste	NULL
__	NULL
K	NULL
‘	NULL
D	NULL
‘	NULL
'	NULL
2	NULL
30	NULL
UAS	NULL
-CAT	NULL
O	NULL
u	NULL
)	NULL
)	NULL
w-	NULL
un	NULL
}	NULL
x==	NULL
To	NULL
_|	NULL
1	NULL
Reporter	NULL
alone	NULL
501	NULL
”	NULL
Ll	NULL
“	NULL
fl	NULL
!	NULL

IVAW	NULL
(	NULL
AAPA	NULL
HL	NULL
C	NULL
C	NULL
1p	NULL
g	NULL
»	NULL
|	NULL
2	NULL
W7-9300	NULL
(	NULL
1-743	NULL
aa	NULL
)	NULL
3	NULL
Y638A	NULL
mutant	NULL
g	NULL
D	NULL
:	NULL
4	NULL
Helix	NULL
I	NULL
mutant	NULL
3	NULL
;	NULL
20	NULL
5	NULL
Helix	NULL
II	NULL
mutant	NULL
Twins	NULL
“	NULL
6	NULL
Helix	NULL
VIII	NULL
mutant	NULL
L	NULL
ta	NULL
sa	NULL
is	NULL
|	NULL
7	NULL
.	NULL

Helix	NULL
IX	NULL
mutant	NULL
(	NULL
H+	NULL
~	NULL
\\a6	NULL
)	NULL
8	NULL
-	NULL
Helix	NULL
I/Y638A	NULL
mutant	NULL
``	NULL
TXA	NULL
g	NULL
o	NULL
9	NULL
Helix	NULL
II/IX	NULL
mutant	NULL
k	NULL
llTia'nla'-	NULL
``	NULL
-	NULL
'	NULL
:	NULL
T.	NULL
Frew	NULL
'	NULL
&	NULL
.	NULL

°	NULL
w	NULL
?	NULL

“	NULL
fit-£11	NULL
LP	NULL
f	NULL
'	NULL
P	NULL
5	NULL
Helix	NULL
I1	NULL
mutant	NULL
Helix	NULL
IX	NULL
mutant	NULL
on	NULL
pie	NULL
ane	NULL
aig	NULL
na-nlng	NULL
iv	NULL
Man	NULL
Tui	NULL
vis	NULL
{	NULL
)	NULL
-	NULL
(	NULL
fa	NULL
)	NULL
oln	NULL
Cin	NULL
R/V	NULL
R	NULL
_E	NULL
)	NULL
um	NULL
£	NULL
]	NULL
Nit	NULL
)	NULL
t	NULL
)	NULL
OC	NULL
(	NULL
|	NULL
1	NULL
Gur	NULL
XJ	NULL
)	NULL
{	NULL
v	NULL
{	NULL
/v	NULL
{	NULL
/v	NULL
_EJuu	NULL
]	NULL
vit	NULL
)	NULL
t	NULL
]	NULL
1x	NULL
\	NULL
+	NULL
um	NULL
rv	NULL
ry	NULL
av	NULL
0	NULL
a	NULL
1	NULL
23	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
wt	NULL
_Y-A	NULL
1	NULL
_L	NULL
Vill	NULL
IX	NULL
IYA	NULL
&	NULL
,	NULL
Gal4-p300	NULL
-|	NULL
eilh	NULL
«	NULL
am	NULL
°	NULL
``	NULL
Unstim	NULL
PMA/Ionomycin	NULL
a-Gal4	NULL
DBD	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Cis-element	NULL
recruitment	NULL
and	NULL
transactivation	NULL
potential	NULL
of	NULL
p300	NULL
show	NULL
differential	NULL
dependence	NULL
on	NULL
structural	NULL
domains	NULL
within	NULL
the	NULL
N	NULL
terminus	NULL
of	NULL
p300	NULL
.	NULL

Pane	NULL
!	NULL

A	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
as	NULL
indicated	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus-	NULL
«	NULL
B	NULL
,	NULL
4	NULL
ug	NULL
of	NULL
3X-AP-1	NULL
,	NULL
4	NULL
ug	NULL
of	NULL
SX	NULL
NF-AT	NULL
,	NULL
or	NULL
4	NULL
ug	NULL
of	NULL
NFIL-2A	NULL
reporter	NULL
plasmids	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
p300	NULL
1-748	NULL
expression	NULL
vectors	NULL
containing	NULL
either	NULL
the	NULL
wild	NULL
type	NULL
or	NULL
Y638A	NULL
mutation	NULL
in	NULL
the	NULL
p300	NULL
KIX	NULL
domain	NULL
(	NULL
see	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
stimulated	NULL
with	NULL
phorbol	NULL
ester	NULL
(	NULL
PMA	NULL
)	NULL
and	NULL
ionomycin	NULL
prior	NULL
to	NULL
harvest	NULL
and	NULL
assay	NULL
for	NULL
reporter	NULL
plasmid	NULL
activity	NULL
.	NULL

Panel	NULL
B	NULL
,	NULL
schematic	NULL
diagram	NULL
of	NULL
the	NULL
proline-disrupted	NULL
predicted	NULL
a-helical	NULL
segments	NULL
of	NULL
the	NULL
p300	NULL
N	NULL
terminus	NULL
.	NULL

Each	NULL
putative	NULL
helix	NULL
was	NULL
scored	NULL
by	NULL
its	NULL
percent	NULL
sequence	NULL
identity	NULL
to	NULL
analogous	NULL
regions	NULL
in	NULL
CBP	NULL
.	NULL

Helical	NULL
wheel	NULL
diagrams	NULL
show	NULL
the	NULL
positions	NULL
of	NULL
the	NULL
proline	NULL
substitutions	NULL
for	NULL
helix	NULL
II	NULL
and	NULL
helix	NULL
IX	NULL
(	NULL
see	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
)	NULL
.	NULL

The	NULL
inset	NULL
shows	NULL
an	NULL
immunoblot	NULL
analysis	NULL
of	NULL
Gal4-p800	NULL
mutant	NULL
expression	NULL
relative	NULL
to	NULL
wild	NULL
type	NULL
,	NULL
in	NULL
stimulated	NULL
Jurkat	NULL
T-cells	NULL
.	NULL

Panel	NULL
C	NULL
,	NULL
Jurkat	NULL
T-cells	NULL
were	NULL
transfected	NULL
with	NULL
4	NULL
ug	NULL
of	NULL
CD28RE-TRE	NULL
(	NULL
top	NULL
)	NULL
or	NULL
2	NULL
ug	NULL
of	NULL
UAS-CAT	NULL
(	NULL
bottom	NULL
)	NULL
reporter	NULL
plasmids	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
3	NULL
ug	NULL
of	NULL
the	NULL
indicated	NULL
Gal4-p300	NULL
wild	NULL
type	NULL
and	NULL
mutant	NULL
expression	NULL
vectors	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
stimulated	NULL
with	NULL
phorbol	NULL
ester	NULL
and	NULL
ionomycin	NULL
prior	NULL
to	NULL
harvest	NULL
and	NULL
assay	NULL
for	NULL
CAT	NULL
expression	NULL
.	NULL

the	NULL
helix	NULL
II	NULL
domain	NULL
is	NULL
also	NULL
known	NULL
to	NULL
contain	NULL
a	NULL
nuclear	NULL
hormone	NULL
receptor	NULL
binding	NULL
motif	NULL
,	NULL
(	NULL
LXXLL	NULL
)	NULL
,	NULL
which	NULL
is	NULL
a	NULL
suspected	NULL
target	NULL
for	NULL
steroid	NULL
hormone-mediated	NULL
repression	NULL
of	NULL
p300/CBP-con-trolled	NULL
genes	NULL
(	NULL
89	NULL
,	NULL
40	NULL
)	NULL
.	NULL

DISCUSSION	NULL
p300	NULL
plays	NULL
a	NULL
quintessential	NULL
role	NULL
as	NULL
an	NULL
adaptor	NULL
by	NULL
providing	NULL
the	NULL
necessary	NULL
scaffolding	NULL
to	NULL
link	NULL
diverse	NULL
factors	NULL
in	NULL
an	NULL
active	NULL
transcriptional	NULL
complex	NULL
at	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

A	NULL
prominent	NULL
feature	NULL
of	NULL
the	NULL
IL-2	NULL
enhanceosome	NULL
which	NULL
distinguishes	NULL
it	NULL
from	NULL
others	NULL
,	NULL
such	NULL
as	NULL
the	NULL
prototypical	NULL
interferon-f	NULL
promoter	NULL
(	NULL
41	NULL
)	NULL
,	NULL
is	NULL
the	NULL
capacity	NULL
of	NULL
the	NULL
N-terminal	NULL
module	NULL
of	NULL
p300	NULL
(	NULL
743	NULL
amino	NULL
acids	NULL
)	NULL
alone	NULL
to	NULL
assemble	NULL
the	NULL
enhanceosome	NULL
and	NULL
activate	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

This	NULL
difference	NULL
is	NULL
particularly	NULL
notable	NULL
because	NULL
the	NULL
N-terminal	NULL
module	NULL
not	NULL
only	NULL
lacks	NULL
histone	NULL
acetyltransferase	NULL
activity	NULL
but	NULL
is	NULL
missing	NULL
interaction	NULL
domains	NULL
for	NULL
po-lymerase	NULL
II	NULL
,	NULL
TFIIB	NULL
,	NULL
and	NULL
other	NULL
basal	NULL
factors	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

These	NULL
observation	NULL
suggests	NULL
that	NULL
the	NULL
interaction	NULL
of	NULL
p300	NULL
with	NULL
polym-erase	NULL
II	NULL
(	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
may	NULL
be	NULL
a	NULL
redundant	NULL
or	NULL
sequential	NULL
feature	NULL
of	NULL
the	NULL
enhanceosome	NULL
which	NULL
can	NULL
be	NULL
compensated	NULL
for	NULL
by	NULL
interactions	NULL
with	NULL
other	NULL
coactivator	NULL
complexes	NULL
such	NULL
as	NULL
mediator	NULL
(	NULL
for	NULL
discussions	NULL
,	NULL
see	NULL
Ref	NULL
.	NULL

50	NULL
)	NULL
.	NULL

It	NULL
is	NULL
also	NULL
possible	NULL
that	NULL
p300	NULL
may	NULL
interact	NULL
with	NULL
promoters	NULL
as	NULL
a	NULL
dimer	NULL
,	NULL
although	NULL
no	NULL
evidence	NULL
of	NULL
p300	NULL
oligomerization	NULL
has	NULL
ever	NULL
been	NULL
reported	NULL
.	NULL

Prior	NULL
studies	NULL
with	NULL
isolated	NULL
enhancer	NULL
elements	NULL
have	NULL
shown	NULL
differential	NULL
requirements	NULL
for	NULL
the	NULL
intrinsic	NULL
histone	NULL
acetyl-transferase	NULL
activity	NULL
of	NULL
p300/CBP	NULL
(	NULL
47	NULL
)	NULL
.	NULL

However	NULL
,	NULL
few	NULL
of	NULL
these	NULL
studies	NULL
have	NULL
extended	NULL
this	NULL
observation	NULL
to	NULL
whole	NULL
functional	NULL
promoters	NULL
in	NULL
vitro	NULL
or	NULL
in	NULL
vivo	NULL
,	NULL
and	NULL
none	NULL
has	NULL
shown	NULL
the	NULL
selective	NULL
modular	NULL
requirement	NULL
of	NULL
p300	NULL
domains	NULL
as	NULL
demonstrated	NULL
in	NULL
this	NULL
work	NULL
.	NULL

To	NULL
the	NULL
contrary	NULL
,	NULL
some	NULL
promoters	NULL
,	NULL
such	NULL
as	NULL
the	NULL
interferon-	NULL
gene	NULL
,	NULL
are	NULL
repressed	NULL
by	NULL
the	NULL
N	NULL
terminus	NULL
of	NULL
the	NULL
p300/CBP	NULL
module	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Understanding	NULL
the	NULL
differential	NULL
requirements	NULL
of	NULL
promoters	NULL
for	NULL
specific	NULL
regulatory	NULL
and	NULL
enzymatic	NULL
modules	NULL
of	NULL
p300	NULL
will	NULL
be	NULL
an	NULL
important	NULL
challenge	NULL
in	NULL
the	NULL
future	NULL
for	NULL
determining	NULL
how	NULL
they	NULL
are	NULL
targeted	NULL
selectively	NULL
by	NULL
molecular	NULL
signaling	NULL
events	NULL
in	NULL
activated	NULL
T-cells	NULL
.	NULL

This	NULL
is	NULL
particularly	NULL
true	NULL
given	NULL
that	NULL
the	NULL
N	NULL
terminus	NULL
of	NULL
p300	NULL
is	NULL
the	NULL
region	NULL
with	NULL
least	NULL
homology	NULL
to	NULL
CBP	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
the	NULL
use	NULL
of	NULL
the	NULL
proline	NULL
mutations	NULL
to	NULL
dissect	NULL
the	NULL
functional	NULL
domains	NULL
within	NULL
the	NULL
p300	NULL
N-terminal	NULL
module	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
will	NULL
be	NULL
an	NULL
effective	NULL
tool	NULL
in	NULL
determining	NULL
the	NULL
structural	NULL
requirements	NULL
for	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
T-cell	NULL
Signaling	NULL
via	NULL
p300-Mediated	NULL
CREB-Rel	NULL
Cross-talk	NULL
3J¥Y4L-3¥Y8Z20D	NULL
IL-2	NULL
proximal	NULL
promoter	NULL
``	NULL
enhanceosome	NULL
``	NULL
FiG	NULL
.	NULL

6	NULL
.	NULL

Schematic	NULL
diagram	NULL
of	NULL
hypothetical	NULL
enhanceosome	NULL
complex	NULL
assembled	NULL
with	NULL
p300	NULL
at	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

The	NULL
N-terminal	NULL
portion	NULL
of	NULL
p300	NULL
is	NULL
represented	NULL
as	NULL
a	NULL
functionally	NULL
separate	NULL
domain	NULL
or	NULL
module	NULL
(	NULL
see	NULL
``	NULL
Discussion	NULL
``	NULL
)	NULL
.	NULL

the	NULL
recruitment	NULL
of	NULL
this	NULL
module	NULL
at	NULL
different	NULL
promoters	NULL
.	NULL

Similar	NULL
analyses	NULL
will	NULL
have	NULL
to	NULL
be	NULL
performed	NULL
for	NULL
the	NULL
domain	NULL
structure	NULL
of	NULL
CBP	NULL
N	NULL
terminus	NULL
.	NULL

A	NULL
repetitive	NULL
feature	NULL
of	NULL
the	NULL
combinatorial	NULL
nature	NULL
of	NULL
the	NULL
IL-2	NULL
elements	NULL
is	NULL
the	NULL
pairing	NULL
of	NULL
weak	NULL
binding	NULL
sites	NULL
for	NULL
ubiquitous	NULL
factors	NULL
(	NULL
8-5	NULL
)	NULL
.	NULL

A	NULL
fundamental	NULL
trait	NULL
that	NULL
explains	NULL
these	NULL
differences	NULL
lies	NULL
in	NULL
their	NULL
coordinated	NULL
ability	NULL
to	NULL
recruit	NULL
p300	NULL
.	NULL

The	NULL
recruitment	NULL
of	NULL
p300	NULL
is	NULL
the	NULL
primary	NULL
factor	NULL
that	NULL
accounts	NULL
for	NULL
the	NULL
dramatic	NULL
synergy	NULL
between	NULL
the	NULL
elements	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

It	NULL
is	NULL
also	NULL
the	NULL
main	NULL
explanation	NULL
for	NULL
superinduced	NULL
transactivation	NULL
that	NULL
is	NULL
routinely	NULL
elicited	NULL
from	NULL
multiple	NULL
copy	NULL
enhancer	NULL
elements	NULL
.	NULL

This	NULL
observation	NULL
also	NULL
accounts	NULL
for	NULL
the	NULL
superinduction	NULL
of	NULL
the	NULL
naked	NULL
CD28RE-TRE	NULL
element	NULL
transactivation	NULL
observed	NULL
upon	NULL
overexpression	NULL
of	NULL
p300	NULL
(	NULL
10	NULL
)	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
single	NULL
CD28RE-TRE	NULL
and	NULL
its	NULL
bound	NULL
elements	NULL
have	NULL
a	NULL
much	NULL
lower	NULL
affinity	NULL
for	NULL
p300	NULL
;	NULL
therefore	NULL
,	NULL
enforced	NULL
expression	NULL
of	NULL
p300	NULL
is	NULL
able	NULL
to	NULL
drive	NULL
transactivation	NULL
from	NULL
the	NULL
CD28RE-TRE	NULL
by	NULL
mass	NULL
action	NULL
.	NULL

Simply	NULL
put	NULL
,	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
a	NULL
tandem	NULL
array	NULL
of	NULL
non-identical	NULL
cis-elements	NULL
(	NULL
a	NULL
``	NULL
composite	NULL
of	NULL
composites	NULL
``	NULL
)	NULL
that	NULL
act	NULL
together	NULL
as	NULL
a	NULL
multivalent	NULL
binding	NULL
interface	NULL
for	NULL
specific	NULL
p300	NULL
modules	NULL
.	NULL

By	NULL
this	NULL
thinking	NULL
,	NULL
different	NULL
p300-controlled	NULL
promoters	NULL
should	NULL
fall	NULL
into	NULL
categories	NULL
that	NULL
can	NULL
be	NULL
distinguished	NULL
by	NULL
the	NULL
number	NULL
and	NULL
types	NULL
of	NULL
cis-elements	NULL
that	NULL
are	NULL
necessary	NULL
to	NULL
recruit	NULL
specific	NULL
p300	NULL
modules	NULL
to	NULL
achieve	NULL
transcriptional	NULL
activation	NULL
.	NULL

The	NULL
mutational	NULL
analysis	NULL
of	NULL
the	NULL
N	NULL
terminus	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
will	NULL
help	NULL
define	NULL
the	NULL
specificity	NULL
of	NULL
these	NULL
binding	NULL
interfaces	NULL
at	NULL
different	NULL
promoters	NULL
.	NULL

Although	NULL
previous	NULL
studies	NULL
have	NULL
shown	NULL
a	NULL
direct	NULL
link	NULL
between	NULL
.	NULL

CREB/ATF	NULL
activity	NULL
at	NULL
the	NULL
CD28RE-TRE	NULL
and	NULL
CREB	NULL
dominant	NULL
negative	NULL
transgenic	NULL
studies	NULL
show	NULL
inhibition	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
(	NULL
10	NULL
,	NULL
42	NULL
)	NULL
,	NULL
the	NULL
identification	NULL
of	NULL
the	NULL
B-Zip	NULL
components	NULL
that	NULL
interact	NULL
with	NULL
the	NULL
CD28RE-TRE	NULL
remains	NULL
controversial	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Other	NULL
studies	NULL
have	NULL
implied	NULL
that	NULL
a	NULL
Fos/Jun	NULL
AP-1	NULL
complex	NULL
is	NULL
the	NULL
active	NULL
partner	NULL
that	NULL
interacts	NULL
with	NULL
the	NULL
TRE	NULL
(	NULL
NFIL-2B	NULL
)	NULL
portion	NULL
of	NULL
the	NULL
composite	NULL
CD28RE-TRE	NULL
(	NULL
11	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
presence	NULL
of	NULL
AP-1	NULL
has	NULL
never	NULL
been	NULL
identified	NULL
in	NULL
an	NULL
in	NULL
vivo	NULL
complex	NULL
that	NULL
binds	NULL
the	NULL
CD28RE-TRE	NULL
,	NULL
prior	NULL
work	NULL
by	NULL
others	NULL
has	NULL
suggested	NULL
that	NULL
Fos/Jun	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
the	NULL
CD28RE-TRE	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Dominant	NULL
negative	NULL
CREB	NULL
expression	NULL
vectors	NULL
repress	NULL
the	NULL
CD28RE-TRE	NULL
without	NULL
repressing	NULL
a	NULL
consensus	NULL
AP-1	NULL
element	NULL
(	NULL
10	NULL
)	NULL
,	NULL
and	NULL
past	NULL
studies	NULL
show	NULL
that	NULL
dominant	NULL
negative	NULL
Jun	NULL
expression	NULL
does	NULL
not	NULL
repress	NULL
the	NULL
CD28RE-TRE	NULL
even	NULL
though	NULL
it	NULL
potently	NULL
inhibits	NULL
transactivation	NULL
of	NULL
both	NULL
NF-AT	NULL
27655	NULL
and	NULL
consensus	NULL
AP-1	NULL
enhancers	NULL
(	NULL
44	NULL
)	NULL
.	NULL

In	NULL
another	NULL
study	NULL
,	NULL
the	NULL
CD28RE-TRE	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
repressed	NULL
in	NULL
T-cells	NULL
by	NULL
activation	NULL
of	NULL
ICER	NULL
,	NULL
an	NULL
endogenous	NULL
CREB	NULL
dominant	NULL
negative	NULL
induced	NULL
by	NULL
elevations	NULL
in	NULL
intracellular	NULL
cAMP	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
consistent	NULL
with	NULL
recent	NULL
observations	NULL
that	NULL
Tax	NULL
expression	NULL
represses	NULL
AP-1	NULL
transactivation	NULL
by	NULL
competing	NULL
for	NULL
AP-1	NULL
binding	NULL
to	NULL
p300/CBP	NULL
(	NULL
45	NULL
)	NULL
,	NULL
work	NULL
in	NULL
this	NULL
report	NULL
confirms	NULL
that	NULL
both	NULL
a	NULL
consensus	NULL
AP-1	NULL
enhancer	NULL
and	NULL
NF-AT	NULL
are	NULL
repressed	NULL
rather	NULL
than	NULL
stimulated	NULL
by	NULL
Tax	NULL
.	NULL

An	NULL
explanation	NULL
for	NULL
the	NULL
discrepancy	NULL
between	NULL
these	NULL
findings	NULL
and	NULL
those	NULL
published	NULL
by	NULL
Sun	NULL
and	NULL
co-workers	NULL
(	NULL
21	NULL
)	NULL
,	NULL
who	NULL
suggest	NULL
that	NULL
Tax	NULL
up-regulates	NULL
NF-AT	NULL
transactivation	NULL
,	NULL
may	NULL
lie	NULL
in	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
element	NULL
in	NULL
their	NULL
study	NULL
contained	NULL
multiple	NULL
tandem	NULL
copies	NULL
of	NULL
only	NULL
the	NULL
CD28RE	NULL
half	NULL
of	NULL
the	NULL
CD28RE-TRE	NULL
site	NULL
in	NULL
binding	NULL
and	NULL
transactivation	NULL
studies	NULL
with	NULL
overexpressed	NULL
NF-AT	NULL
.	NULL

Our	NULL
findings	NULL
do	NULL
not	NULL
exclude	NULL
a	NULL
role	NULL
for	NULL
AP-1	NULL
family	NULL
members	NULL
at	NULL
the	NULL
IL-2	NULL
promoter	NULL
because	NULL
there	NULL
is	NULL
overwhelming	NULL
evidence	NULL
that	NULL
Fos/Jun	NULL
plays	NULL
a	NULL
significant	NULL
role	NULL
as	NULL
a	NULL
congener	NULL
at	NULL
the	NULL
distal	NULL
NF-AT	NULL
site	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
B-Zip	NULL
dimer	NULL
composition	NULL
at	NULL
the	NULL
CD28RE-TRE	NULL
is	NULL
not	NULL
clear	NULL
.	NULL

An	NULL
AP-UVCREB	NULL
heterodimer	NULL
(	NULL
e.g	NULL
.	NULL

Jun/ATF-2	NULL
or	NULL
CREB2/Fra	NULL
)	NULL
could	NULL
be	NULL
the	NULL
true	NULL
active	NULL
B-Zip	NULL
dimer	NULL
at	NULL
the	NULL
CD28RE-TRE	NULL
.	NULL

In	NULL
all	NULL
likelihood	NULL
,	NULL
there	NULL
is	NULL
probably	NULL
a	NULL
stochastic	NULL
distribution	NULL
of	NULL
B-Zip	NULL
heterodimers	NULL
that	NULL
target	NULL
the	NULL
CD28RE-TRE	NULL
in	NULL
any	NULL
given	NULL
activated	NULL
T-cell	NULL
.	NULL

Certainly	NULL
the	NULL
current	NULL
evidence	NULL
presented	NULL
in	NULL
this	NULL
paper	NULL
does	NULL
more	NULL
to	NULL
rule	NULL
in	NULL
a	NULL
role	NULL
for	NULL
CREB/ATF	NULL
rather	NULL
than	NULL
rule	NULL
out	NULL
one	NULL
for	NULL
fos/jun	NULL
at	NULL
the	NULL
CD28RE-TRE	NULL
.	NULL

It	NULL
was	NULL
suggested	NULL
previously	NULL
that	NULL
AP-1	NULL
may	NULL
be	NULL
a	NULL
molecular	NULL
target	NULL
for	NULL
T-cell	NULL
anergy	NULL
.	NULL

In	NULL
this	NULL
prior	NULL
study	NULL
,	NULL
a	NULL
reporter	NULL
plasmid	NULL
driven	NULL
by	NULL
six	NULL
tandem	NULL
copies	NULL
of	NULL
the	NULL
entire	NULL
CD28RE-TRE	NULL
sequence	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
down-regulated	NULL
in	NULL
anergic	NULL
cells	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
site	NULL
was	NULL
referred	NULL
to	NULL
as	NULL
the	NULL
IL-2	NULL
AP-1	NULL
element	NULL
,	NULL
this	NULL
current	NULL
work	NULL
provides	NULL
dramatic	NULL
evidence	NULL
in	NULL
support	NULL
of	NULL
an	NULL
expanded	NULL
role	NULL
for	NULL
CREB	NULL
family	NULL
members	NULL
and	NULL
p300/CBP	NULL
modules	NULL
in	NULL
T-cell	NULL
anergy	NULL
via	NULL
the	NULL
CD28RE-TRE	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
difference	NULL
shown	NULL
by	NULL
the	NULL
p300	NULL
N-terminal	NULL
mutants	NULL
in	NULL
the	NULL
recruitment	NULL
and	NULL
bypass	NULL
transcriptional	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
suggests	NULL
a	NULL
prominent	NULL
role	NULL
for	NULL
protein-protein	NULL
interaction	NULL
between	NULL
p300	NULL
and	NULL
other	NULL
non-DNA-binding	NULL
regulatory	NULL
complexes	NULL
.	NULL

This	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
a	NULL
promoter-specific	NULL
process	NULL
that	NULL
distinguishes	NULL
among	NULL
various	NULL
coregulator	NULL
complexes	NULL
serving	NULL
as	NULL
coactivators	NULL
or	NULL
corepressors	NULL
at	NULL
the	NULL
IL-2	NULL
gene	NULL
through	NULL
a	NULL
dynamic	NULL
exchange	NULL
linked	NULL
to	NULL
different	NULL
modules	NULL
of	NULL
p300	NULL
(	NULL
see	NULL
51	NULL
and	NULL
references	NULL
cited	NULL
therein	NULL
)	NULL
.	NULL

A	NULL
major	NULL
imperative	NULL
in	NULL
the	NULL
future	NULL
will	NULL
be	NULL
to	NULL
define	NULL
the	NULL
molecular	NULL
rules	NULL
of	NULL
interaction	NULL
which	NULL
determine	NULL
what	NULL
type	NULL
of	NULL
p300-containing	NULL
regulatory	NULL
complexes	NULL
will	NULL
assemble	NULL
at	NULL
various	NULL
target	NULL
genes	NULL
during	NULL
T-cell	NULL
activation	NULL
and	NULL
how	NULL
these	NULL
complexes	NULL
are	NULL
influenced	NULL
by	NULL
upstream	NULL
signaling	NULL
cascades	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Warner	NULL
Greene	NULL
,	NULL
Silvio	NULL
Gutkind	NULL
,	NULL
Kuan-The	NULL
Jeang	NULL
,	NULL
and	NULL
Ulrich	NULL
Siebenlist	NULL
for	NULL
plasmid	NULL
reagents	NULL
and	NULL
Chou	NULL
Zen	NULL
Giam	NULL
,	NULL
Kuan-The	NULL
Jeang	NULL
,	NULL
Kathy	NULL
Kelly	NULL
,	NULL
John	NULL
Brady	NULL
,	NULL
and	NULL
Ulrich	NULL
Siebenlist	NULL
for	NULL
very	NULL
helpful	NULL
discussions	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Goldman	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Tran	NULL
,	NULL
V.	NULL
K.	NULL
,	NULL
and	NULL
Goodman	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1997	NULL
)	NULL
Recent	NULL
Prog	NULL
.	NULL

Horm	NULL
.	NULL

Res	NULL
.	NULL

52	NULL
,	NULL
103-119	NULL
2	NULL
.	NULL

Eckner	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

877	NULL
,	NULL
685-688	NULL
3	NULL
.	NULL

Karin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Hunter	NULL
,	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
Curr	NULL
.	NULL

Biol	NULL
.	NULL

5	NULL
,	NULL
747-757	NULL
4	NULL
.	NULL

Avots	NULL
,	NULL
A.	NULL
,	NULL
Escher	NULL
,	NULL
C.	NULL
,	NULL
Muller-Deubert	NULL
,	NULL
S.	NULL
,	NULL
Neumann	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Immunobiology	NULL
198	NULL
,	NULL
254-258	NULL
5	NULL
.	NULL

Hentsch	NULL
,	NULL
B.	NULL
,	NULL
Mouzaki	NULL
,	NULL
A.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
L.	NULL
,	NULL
Rungger	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20	NULL
,	NULL
2657-2665	NULL
6	NULL
.	NULL

Qian	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

9	NULL
,	NULL
205-212	NULL
7	NULL
.	NULL

Cantrell	NULL
,	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14	NULL
,	NULL
259-274	NULL
8	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
Avots	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Neumann	NULL
,	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1263	NULL
,	NULL
181-200	NULL
9	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
Loh	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
333-842	NULL
10	NULL
.	NULL

Butscher	NULL
,	NULL
W.	NULL
G.	NULL
,	NULL
Powers	NULL
,	NULL
C.	NULL
,	NULL
Olive	NULL
,	NULL
M.	NULL
,	NULL
Vinson	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Gardner	NULL
,	NULL
K.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

278	NULL
,	NULL
552-560	NULL
11	NULL
.	NULL

Shapiro	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
Truitt	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
Imboden	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
,	NULL
4051-4058	NULL
12	NULL
.	NULL

Bannister	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Oehler	NULL
,	NULL
T.	NULL
,	NULL
Wilhelm	NULL
,	NULL
D.	NULL
,	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Kouzarides	NULL
,	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
27656	NULL
18	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

28	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

Oncogene	NULL
11	NULL
,	NULL
2509-2514	NULL
Poiesz	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
Ruscetti	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
Gazdar	NULL
,	NULL
A.	NULL
F.	NULL
,	NULL
Bunn	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Minna	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1980	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

77	NULL
,	NULL
7415-7419	NULL
Yoshida	NULL
,	NULL
M.	NULL
,	NULL
Seiki	NULL
,	NULL
M.	NULL
,	NULL
Yamaguchi	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Takatsuki	NULL
,	NULL
K.	NULL
(	NULL
1984	NULL
)	NULL
Proc	NULL
.	NULL

Naf	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

81	NULL
,	NULL
2584-2587	NULL
Bex	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Gaynor	NULL
,	NULL
R.	NULL
B	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Methods	NULL
16	NULL
,	NULL
83-94	NULL
Smith	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1990	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

4	NULL
,	NULL
1875-1885	NULL
Munoz	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Israel	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunobiology	NULL
198	NULL
,	NULL
128-136	NULL
Sickevitz	NULL
,	NULL
M.	NULL
,	NULL
Feinberg	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
Holbrook	NULL
,	NULL
N.	NULL
,	NULL
Wong-Staal	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

84	NULL
,	NULL
5889-5398	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Bohnlein	NULL
,	NULL
E.	NULL
,	NULL
Lowenthal	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Wano	NULL
,	NULL
Y.	NULL
,	NULL
Franza	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1988	NULL
)	NULL
Science	NULL
241	NULL
,	NULL
1652-1655	NULL
Himes	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Katsikeros	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Shannon	NULL
,	NULL
M.	NULL
F.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

70	NULL
,	NULL
4001-4008	NULL
Good	NULL
,	NULL
L.	NULL
,	NULL
Maggirwar	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
and	NULL
Sun	NULL
,	NULL
S.	NULL
C.	NULL
(	NULL
1996	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

15	NULL
,	NULL
3744-3750	NULL
Yasui	NULL
,	NULL
H.	NULL
,	NULL
Butscher	NULL
,	NULL
W.	NULL
,	NULL
Cohen	NULL
,	NULL
M.	NULL
,	NULL
Spriggs	NULL
,	NULL
N.	NULL
,	NULL
Wersto	NULL
,	NULL
R.	NULL
,	NULL
Kohn	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
Liotta	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Gardner	NULL
,	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
28762-28770	NULL
Semmes	NULL
,	NULL
O.	NULL
J.	NULL
,	NULL
Barret	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Dang	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
and	NULL
Jeang	NULL
,	NULL
K.	NULL
T.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
9730-9738	NULL
Arany	NULL
,	NULL
Z.	NULL
,	NULL
Newsome	NULL
,	NULL
D.	NULL
,	NULL
Oldread	NULL
,	NULL
E.	NULL
,	NULL
Livingston	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
and	NULL
Eckner	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
$	NULL
74	NULL
,	NULL
81-84	NULL
Yuan	NULL
,	NULL
W.	NULL
,	NULL
Condorelli	NULL
,	NULL
G.	NULL
,	NULL
Caruso	NULL
,	NULL
M.	NULL
,	NULL
Felsani	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Giordano	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
9009-9018	NULL
Abn	NULL
,	NULL
S.	NULL
,	NULL
Olive	NULL
,	NULL
M.	NULL
,	NULL
Aggarwal	NULL
,	NULL
S.	NULL
,	NULL
Krylov	NULL
,	NULL
D.	NULL
,	NULL
Ginty	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
and	NULL
Vinson	NULL
,	NULL
C.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
967-977	NULL
Kanno	NULL
,	NULL
T.	NULL
,	NULL
Brown	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
11745-11748	NULL
Deleted	NULL
in	NULL
proof	NULL
Gardner	NULL
,	NULL
K.	NULL
,	NULL
Moore	NULL
,	NULL
T.	NULL
C.	NULL
,	NULL
Davis-Smyth	NULL
,	NULL
T.	NULL
,	NULL
Krutzsch	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Levens	NULL
,	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
82963-32971	NULL
Powers	NULL
,	NULL
C.	NULL
,	NULL
Krutzsch	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Gardner	NULL
,	NULL
K.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
30089-30095	NULL
Manger	NULL
,	NULL
B.	NULL
,	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
Imboden	NULL
,	NULL
J.	NULL
,	NULL
Laing	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Stobo	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

189	NULL
,	NULL
2755-2760	NULL
36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

T-cell	NULL
Signaling	NULL
via	NULL
p300-Mediated	NULL
CREB-Rel	NULL
Cross-talk	NULL
32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Imboden	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Adv	NULL
.	NULL

Immunol	NULL
.	NULL

41	NULL
,	NULL
1-88	NULL
Deleted	NULL
in	NULL
proof	NULL
Giordano	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Avantaggiati	NULL
,	NULL
M.	NULL
L.	NULL
(	NULL
1999	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
.	NULL

Physiol	NULL
.	NULL

181	NULL
,	NULL
218-230	NULL
Radhakrishnan	NULL
,	NULL
I.	NULL
,	NULL
Perez-Alvarado	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
Parker	NULL
,	NULL
D.	NULL
,	NULL
Dyson	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Montminy	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
Wright	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1997	NULL
)	NULL
Cell	NULL
91	NULL
,	NULL
741-752	NULL
Chrivia	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Kwok	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Lamb	NULL
,	NULL
N.	NULL
,	NULL
Hagiwara	NULL
,	NULL
M.	NULL
,	NULL
Montminy	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
Goodman	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
Nature	NULL
865	NULL
,	NULL
855-859	NULL
Zhong	NULL
,	NULL
H.	NULL
,	NULL
Voll	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
and	NULL
Ghosh	NULL
,	NULL
S.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
1	NULL
,	NULL
661-671	NULL
Gerritsen	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Williams	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Neish	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Moore	NULL
,	NULL
S.	NULL
,	NULL
Shi	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Collins	NULL
,	NULL
T.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

94	NULL
,	NULL
2927-2982	NULL
Heery	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Kalkhoven	NULL
,	NULL
E.	NULL
,	NULL
Hoare	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Parker	NULL
,	NULL
M.	NULL
G.	NULL
(	NULL
1997	NULL
)	NULL
Nature	NULL
887	NULL
,	NULL
733-736	NULL
Bodor	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Habener	NULL
,	NULL
J.	NULL
F.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

278	NULL
,	NULL
9544-9551	NULL
Merika	NULL
,	NULL
M.	NULL
,	NULL
Williams	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Chen	NULL
,	NULL
G.	NULL
,	NULL
Collins	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Thanos	NULL
,	NULL
D.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
1	NULL
,	NULL
277-287	NULL
Barton	NULL
,	NULL
K.	NULL
,	NULL
Muthusamy	NULL
,	NULL
N.	NULL
,	NULL
Chanyangam	NULL
,	NULL
M.	NULL
,	NULL
Fischer	NULL
,	NULL
C.	NULL
,	NULL
Clendenin	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
.	NULL

Leiden	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Nature	NULL
879	NULL
,	NULL
81-85	NULL
Risse	NULL
,	NULL
G.	NULL
,	NULL
Neuberg	NULL
,	NULL
M.	NULL
,	NULL
Hunter	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Verrier	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Muller	NULL
,	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
Environ	NULL
.	NULL

Health	NULL
Perspect	NULL
.	NULL

88	NULL
,	NULL
133-139	NULL
Petrak	NULL
,	NULL
D.	NULL
,	NULL
Memon	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Birrer	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Ashwell	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Zacharchuk	NULL
,	NULL
C.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

158	NULL
,	NULL
2046-2051	NULL
van	NULL
Orden	NULL
,	NULL
K.	NULL
,	NULL
Yan	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Ulloa	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Nyborg	NULL
,	NULL
J.	NULL
K.	NULL
(	NULL
1999	NULL
)	NULL
Oncogene	NULL
18	NULL
,	NULL
3766-3772	NULL
Kang	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Beverly	NULL
,	NULL
B.	NULL
,	NULL
Tran	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Brorson	NULL
,	NULL
K.	NULL
,	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
and	NULL
Lenardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
1184-1188	NULL
Korzus	NULL
,	NULL
E.	NULL
,	NULL
Torchia	NULL
,	NULL
J.	NULL
,	NULL
Rose	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Xu	NULL
,	NULL
L.	NULL
,	NULL
Kurokawa	NULL
,	NULL
R.	NULL
,	NULL
Mclnerney	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Mullen	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Glass	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
and	NULL
Rosenfeld	NULL
,	NULL
M.	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
Science	NULL
279	NULL
,	NULL
703-707	NULL
Simeonidis	NULL
,	NULL
S.	NULL
,	NULL
Stauber	NULL
,	NULL
D.	NULL
,	NULL
Chen	NULL
,	NULL
G.	NULL
,	NULL
Hendrickson	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
and	NULL
Thanos	NULL
,	NULL
D.	NULL
(	NULL
1999	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

96	NULL
,	NULL
49-54	NULL
Glass	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
and	NULL
Rosenfeld	NULL
,	NULL
M.	NULL
G.	NULL
(	NULL
2000	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

14	NULL
,	NULL
121-141	NULL
Vo	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Goodman	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
2001	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

276	NULL
,	NULL
13505-13508	NULL
Chou	NULL
,	NULL
P.	NULL
Y.	NULL
,	NULL
and	NULL
Fasman	NULL
,	NULL
G.	NULL
D.	NULL
(	NULL
1978	NULL
)	NULL
Adv	NULL
.	NULL

Enzymol	NULL
.	NULL

Relat	NULL
.	NULL

Areas	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

47	NULL
,	NULL
45-148	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL
Targeting	NULL
of	NULL
p300	NULL
to	NULL
the	NULL
Interleukin-2	NULL
Promoter	NULL
via	NULL
CREB-Rel	NULL
Cross-talk	NULL
during	NULL
Mitogen	NULL
and	NULL
Oncogenic	NULL
Molecular	NULL
Signaling	NULL
in	NULL
Activated	NULL
T-cells	NULL
Wayne	NULL
G.	NULL
Butscher	NULL
,	NULL
Cynthia	NULL
M.	NULL
Haggerty	NULL
,	NULL
Sohail	NULL
Chaudhry	NULL
and	NULL
Kevin	NULL
Gardner	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

2001	NULL
,	NULL
276:27647-27656.	NULL
doi	NULL
:	NULL
14200	NULL
originally	NULL
published	NULL
online	NULL
April	NULL
19	NULL
,	NULL
2001	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
doi	NULL
:	NULL
10.1074/jbe.MO09614200	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
49	NULL
references	NULL
,	NULL
24	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
/S10-aqf	NULL
/	NULL
wroj	NULL
;	NULL

